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ABSTRACT 
 
Fluorescence imaging has been employed as the gold-standard in molecular imaging. 
However, despite its ubiquitous usage, this technique is only viable for studying molecular 
interactions within a cellular system. Fluorescence imaging is limited by optical diffusion, at 
depths greater than 1 mm, sensitivity of this technique dramatically decreases. As light passes 
through biological tissues, it is scattered and absorbed, resulting in an exponential loss in light 
intensity as a function of sample thickness.  
This physical limitation in fluorescence-based imaging has prevented high resolution 
analyte-specific molecular interaction studies to be performed on multi-cellular organisms. 
Despite optimization of quantum yield and near-infrared absorbance (NIR), the resolution 
achievable to optical imaging is insufficient. To image deeper through tissue, new techniques need 
to be developed. Of interest is the application of the photoacoustic (PA) effect toward imaging. 
The PA effect occurs when optical excitation generates non-radiative relaxation through 
thermoelastic expansion, which produces sound waves that can be detected as ultrasound 
emissions. The PA signal is subject to minimal scattering in comparison to traditional fluorescence 
imaging, as sound scatters considerably less than light through biological matter. Coupled with 
excitation in the NIR window, PA imaging has the potential image in the cm range with micron 
resolution,   
Given the depth penetration PA imaging is capable of, the field lacks analyte-specific probe 
development. The most commonly used analyte specific probes consist of a chromophore and 
reactive handle, which is commonly referred to as a “trigger,” will recognize a specific analyte and 
upon coordination will induce a reaction or a shift in electronics within the system, outputting a 
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colorimetric or fluorescent response. Due to the prolific usage of optical imaging, fluorescence-
based probes have been designed to recognize a multitude of biomolecules and enzymatic activities. 
Within biologically relevant ions, of special interest to the Chan lab is copper. Copper is a vital 
transition metal that acts as an important cofactor for many enzymes in biological systems. 
Misregulation of copper has been linked to multiple neurological disorders, such as Alzheimer’s 
disease. Given its essential function, in vivo imaging of copper has the potential to provide insight 
into its role in disease models. Current PA exogenous contrast agents generate enhanced signal as 
a result of increased concentration in the area of interest. Synthesis of analyte specific PA probes 
provides an important chemical tool required for non-invasive deep-tissue imaging. Similar to 
fluorescent probes, PA probes benefit from absorbance in the NIR window. Due to the lack of 
viable probes in the current field, this work focuses on the design and synthesis of a PA probe 
platform that can be coupled with a variety of triggers and capable of deep-tissue imaging of 
biologically relevant analytes.  
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CHAPTER 1 
INTRODUCTION 
 
Molecular Imaging 
As the medical field develops, a greater emphasis is placed on the ability to monitor 
biological processes in real time. Current imaging techniques are specialized in diagnosis, where 
diseased or healthy tissues are distinguished based on morphology. However, molecular imaging 
seeks to visualize cellular events to uncover additional details concerning biological pathways, 
gene expressions, and signal transduction.1 Rather than image for histology, developing techniques 
in imaging have the potential to provide insight into disease progression and analyte detection. 
Imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography 
(PET) are capable of measuring processes such as tissue oxygenation or cellular proliferation; 
however, these platforms lack adequate spatial resolution to distinguish between 
microenvironments in vivo.2  
Fluorescence-based imaging is currently the gold-standard for optical molecular imaging. 
The proliferation of confocal microscopes and fluorescent reagents has brought on many recent 
advances in the field. The ability to emit light against a dark background allows for high spatial 
and temporal resolution which has made fluorescence-based imaging especially attractive. 
Scientist have developed fluorescent tags to label biological molecules to monitor properties such 
as localization.3 The majority of optical-based probes rely on a change in fluorescence intensity 
upon interaction with the target. Outside of fluorescence, PA imaging has been gaining attention 
as an additional optical imaging tool. Rather than monitoring the fluorescence emission from 
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chromophores, PA imaging reconstructs images using the ultrasound emission generated from 
non-radiative decay.  
 
Principles of Fluorescence Emission 
 Upon optical excitation, chromophores can relax through radiative or non-radiative decay 
mechanisms. Fluorescence imaging is based upon the radiative pathway; while the PA effect 
pertains to relaxation under the non-radiative decay pathway. In the presence of certain 
wavelengths of light, the electrons in the chromophore will be excited to various vibrational level 
in the excited singlet state (Figure 1.1). The electron subsequently undergoes vibrational 
relaxations until relaxing to the first singlet state (S1), the transition from the first singlet state to 
the ground state level produces a fluorescent emission.4 Quantum yield (Φf) describes the 
efficiency in which a chromophore converts light absorbed to light emitted. According to the 
following equation, 
Φ𝑓 =
𝑘𝑟
𝑘𝑟 + 𝑘𝑛𝑟
 
(Eq 1.1) 
the quantum yield can be described as the ratio of the radiative rate constant (𝑘𝑟) to the sum of the 
radiative and non-radiative rate constant (𝑘𝑛𝑟). In other words, the larger the quantum yield, the 
greater the ratio of photons emitted to photons absorbed.5 In molecules without a 100% quantum 
efficiency, energy is lost to a variety of non-radiative pathways, such as vibrational relaxation, 
intersystem crossing, or internal conversion. Since energy is lost, the light emitted has a longer 
wavelength than the absorbance wavelength, described as the Stokes Shift.  
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Photoacoustic Imaging 
In 1880, Alexander Graham Bell first postulated on the phenomena that optical excitation 
is capable of generating an acoustic signal.6 A PA signal is generated from the non-radiative 
vibrational relaxation. The vibrational relaxation of the electron is transferred to the surroundings, 
producing a change in thermal energy. The fluctuation of thermal energy produces thermo-elastic 
expansions which generate sounds waves that can be monitored using ultrasound transducers. In 
PA imaging, the signal strength is inversely proportional to the Φf .Where the less energy released 
as a fluorescent emission, the more energy is released through the non-radiative pathway. 
Additional details is covered in chapter two.  
 
Chromophore Families 
With the development of optical imaging over the past few decades, design and synthesis 
of additional chromophores also is of significant interest. Chromophores fall under two broad 
categories, genetically encoded and small molecule-based. The most renowned genetically 
encoded chromophore was isolated from the jellyfish Aequorea victoria.7 The 238 amino acid 
protein sequence for green fluorescent protein (GFP) has been further mutated into a variety of 
colors and incorporated into numerous organisms. Similarly, small molecule chromophores 
encompasses a broad spectrum of absorbance, from ultra-violet to infrared. Genetically encoded 
chromophores are routinely incorporated into plasmids to aid in elucidation of biological processes 
such as localization, correct protein folding, and protein-protein interactions, to name a few. 
However, in the realm of small molecule analyte monitoring, the relatively large size of genetically 
encoded chromophores complicates potential interaction between analyte and target. Incorporation 
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of genetically encoded chromophores can alter the native environment due to the presence of a 
foreign protein. The interactions observed are possibly perturbed by the addition of the genetically 
encoded chromophore. Small molecule chromophores help minimize these perturbations more so 
than genetically encoded chromophores.   
Fluorescence-based probes are small molecule chromophores designed to react with a 
specific analyte and undergo a conformational shift or a change in electronics. Common families 
of chromophores include coumarin, fluorescein, rhodamine, boron-dipyrromethene, and cyanine, 
to name a few. Novel molecules are being designed and synthesized to expand the current library 
of chromophores, focusing on developing chromophores with NIR absorbance, high Φf, and 
photostability. Due to scattering and absorption of light through biological tissue fluorescence 
imaging is restricted by an optical limit of 1 mm in depth.8 Since there is minimal absorption by 
biological molecules in the NIR window (600-900 nm), there is a similar decrease in background 
signal and auto-fluorescence of from background endogenous biomolecules; additionally a high 
Φf ensures a more efficient conversion of absorbed light to emitted fluorescence.  Characteristics 
such as high Φf, good photostability, a high extinction coefficient and NIR emission also facilitate 
in vivo studies. Chromophores are also screened for cytotoxicity and cross reactivity to determine 
suitability towards in vivo imaging. Ideal chromophores can be developed and applied to cellular 
studies and potentially organisms to uncover new insights into biological processes. 
 
BODIPY  
Among the families of chromophores, of particular interest is the dipyrrometheneboron 
difluoride (BODIPY) based fluorescent probes. These chromophores have been utilized in 
biological sensing and other applications and have shown to have promising photoacoustic 
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potential.9 These dyes tend to absorb in the 480-550 nm range and emit in the 520-600 nm range 
but through structural modifications, the emission can be further red shifted beyond 600 nm. Usage 
of electron-donating groups, extending the conjugation, and rigidifying the structure have been 
utilized as methods to achieve NIR BODIPY dyes.10-12 However, these structural modifications 
also have negative effects such as decreased quantum yields or increased sensitivity to solvents.13 
Despite complex modifications to extend the conjugation of the BODIPY framework, the 
absorbance and emission barely enter into the NIR window. Substitution of the meso carbon with 
a nitrogen heteroatom has been shown to increase the emission maxima into the NIR window 
(Figure 1.2). 
 
Aza-BODIPY 
The aza-dipyrromethene (aza-BODIPY) chromophore, without boron chelation, has been 
synthesized since the 1940s.14 The substitution of the carbon with nitrogen shifts the emission 
maxima to the 680-830 nm range, well within the NIR window. The extinction coefficients for the 
aza-BODIPY are high, ranging from 75,000 to 100,000 M-1 cm-1, while the quantum yields range 
from 0.05 to 0.5.15 Usage of the aza-BODIPY as a fluorescent probe has been well documented. 
Aza-BODIPY analogues have been used for sensing biologically relevant ions such as Na+, K+, 
Hg2+, NO2
-, and NH4
+.16-19 Additionally, aza-BODIPY derivatives have been shown to have 
potential photodynamic therapeutic applications as a photosensitizer. Incorporation of heavy 
atoms into the scaffold facilitates intersystem crossing to increase the production of singlet 
oxygen.20 
Synthesis of the aza-BODIPY core is made through two methods (Figure 1.3).20 The first 
method condenses a 2,4-diaryl-5-nitrosopyrrole with a 2,4-diarylpyrrole. The second method 
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involves reacting the Michael addition of nitromethane to a chalcone with an ammonia source to 
form the aza- BODIPY core. Formation of the chalcone for method b is formed through a Claissen-
Schmidt condensation between acetophenone and benzaldehyde. The synthetic pathway allows for 
facile incorporation of multiple substituents. Similar to the BODIPY platform, electron 
withdrawing substituents, extension of conjugation, and increasing the rigidity of the core can 
increase the absorbance and emission maxima.21-23 
 
Solubility 
The aza-BODIPY scaffold has been shown to have excellent photostability, high extinction 
coefficients and NIR absorbance; but it has also shown to have limited solubility in aqueous 
solutions. The four aryl rings on the aza-BODIPY platform are integral in extending the 
conjugation into the NIR window; however, in the presence of polar solvents, the dye molecules 
tend to form non-emissive aggregates. Application to biological settings relies upon water as the 
fundamental solvent. Given the poor solubility of the aza-BODIPY scaffold, various strategies 
have been employed to synthesize water-soluble derivatives. The most common strategy is the use 
of hydrophilic substituents, such as poly-ethylene glycol chains, sulfonates, carboxylic acids, or 
quaternary ammonium moieties (Figure 1.4).24 These hydrophilic chains increase the water-
solubility without decreasing other optical properties.  
The addition of these solubilizing groups is essential toward synthesis of a water soluble 
aza-BODIPY platform. Despite having a minor impact on optical properties, these solubilizing 
moieties can also influence the synthetic pathways, cell permeability, and localization. One of the 
most common techniques is appending poly ethylene glycol (PEG) moieties. Every subunit of the 
poly-ethylene glycol associates with two to three molecules of water, forming a hydrophilic shield 
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that prevents aggregation and loss of signal.25 The long ethylene glycol chains also add increase 
steric hindrance between multiple aza-BODIPY molecules, further reducing aggregation. At 
physiological pH, the glycol moieties remain uncharged, reducing the non-specific electrostatic 
interactions that may influence other charged molecules. As result, the PEGylated aza-BODIPY 
molecules tend to localize throughout the cytoplasm of the cell.  
Incorporation of charged substituents, such as sulfonate, carboxylic acids, and quaternary 
amines, increase water solubility through ionic repulsion. The aza-BODIPY is decorated in 
similarly charged groups that attract the polar water molecules and repel other similarly charged 
molecules, preventing the formation of aggregates. Additional studies have found incorporation of 
phosphorous instead of boron significantly increases water solubility. In a process similar to the 
synthesis of the aza-BODIPY, the chelation uses phosphorous oxychloride rather than boron 
trifluoride diethyletherate to form the aza-PODIPY molecule.26 Use of quaternary amines have 
also allowed the aza-BODIPY platform to be tuned for usage as a pH sensor. 
 
pH Sensors 
Intracellular pH environments have been shown to play an important role in cellular 
functions. Fluctuations in pH can signify cellular events such as endocytosis or apoptosis. 
Additionally, local environments in cells can vary in pH as well as across different cell types such 
as healthy and cancerous cells. 2 7Studies of the synthesis of various pH responsive fluorescent 
probes have been conducted as a method of studying the impact of pH on cellular functions. 
Fluorescent probes provide high spatial resolution and minimal cell disruption over other non-
optical techniques, such as microelectrodes. Given the NIR absorbance and fluorescence of the 
aza-BODIPY platform, multiple studies have synthesized a pH responsive aza-BODIPY probe.  
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The pH responsiveness is derived from tuning the periphery substituents on the aza-
BODIPY platform. Usage of substituents with pKas in the physiological range allow for a 
photoinduced electron transfer event to occur which causes a change in fluorescence. Tertiary 
amines and phenols have been extensively used in pH sensitive molecules because the apparent 
pKas fall within the physiological window. In their protonated state, the fluorescence is “turned 
on” while in basic conditions, the molecules become non-fluorescent due to the photoinduced 
electron transfer process.28 Tuning of the pKa further broadens the applicability of the aza-
BODIPY pH sensor. The periphery substituents on the aza-BODIPY core show similar trends in 
tuning the pKa of phenols. The presence of electronegative groups ortho to the phenol drops the 
apparent pKa in comparison to the unsubstituted phenol.29 
In addition to a change in the fluorescence from the protonated to the deprotonated states, 
the fluorescent probe also undergoes a change in absorbance. In the protonated and non-fluorescent 
state, the absorbance is a shorter wavelength. Upon deprotonation, the absorbance undergoes a 
bathochromic shift (Figure 1.5).30 Tuning of the aniline and phenol pKa facilitates their usage as 
fluorescent pH sensors, it also allows for bioconjugation of analyte specific moieties. The pH 
responsive element can be capped to prevent formation of the non-fluorescent state. Upon cleavage 
of the analyte specific moiety, the aza-BODIPY can then undergo a bathochromic shift. However, 
since the deprotonation event is usually accompanied by a decrease in fluorescence, the strategy 
is not ideally suitable for fluorescence-based imaging.  
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CHAPTER 2 
PHOTOACOUSTIC PRINCIPLES 
 
Photoacoustic Principles 
Alexander Bell discovered the production of sound from the action of light.6 By placing a 
sample of selenium in platinum coils, Bell shown light intermittently on the sample and recorded 
a perceptible sound when the light hit the sample.32 The photoacoustic effect phenomena did not 
develop until Rosencwaig and his researchers provided a theoretical basis.33 The photoacoustic 
signal is generated when electromagnetic radiation excites a sample and causes a thermal state 
change (Figure 2.1). The molecules that absorbed the radiation relax using non-radiative processes, 
such as collisions with other molecules to generate the thermal change in the sample. The 
expansion and subsequent contractions caused by the thermoelastic change also causes fluctuations 
in the pressure of the local environment.34 The pressure fluctuation produces sound waves that can 
then be detected using microphones, piezoelextric devices, or ultrasound transducers.35 The first 
application of this technique was the detection of trace metal ions in a gaseous sample.36 Gas 
samples are loaded into a small chamber, irradiated with light and detected with a gas-microphone 
detector. PA spectroscopy of gasses can detect low levels of particles in complex gas mixtures, on 
the scale of parts per trillion. Because of its high detection sensitivity, PA spectroscopy has also 
been applied to trace analysis of solids and to study weak optical transitions.37 Photoacoustic 
Raman spectroscopy has also been developed to study material compositions.38 Stimulated Raman 
scattering results in the excitation of the gas molecules which generates translational heating to 
produce the pressure waves that are detected as sound waves by a microphone. 
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 Fluorescence imaging has the potential to be a non-evasive method for the elucidation of 
biological pathways in real-time. However, current high resolution optical techniques such as 
confocal and two-photon microscopy are limited by diffraction. As light passes through tissue, it 
is absorbed and scattered, resulting in an exponential loss in intensity. Because of this scattering 
effect, optical imaging has depth limits. The depth limit which affects fluorescence-based imaging 
is the distance that the light stays in the quasiballistic regime. In the quasiballistic regime, photons 
have undergone few scattering events and still retain part of the original incidence direction. 
Outside of the quasiballistic regime, photons can penetrate but are too scrambled to be focused. 
This depth limit restricts high resolution imaging to less than l mm.39 The other depth limit 
describes the depth which the photons are become too diffuse for practical purposes, this is 
considered as the hard depth limit for imaging at 5-7 cm.40 Despite being able to provide 
visualization of many biological processes, fluorescence and other optical techniques are limited 
to cellular studies in order to maintain adequate resolution. 
On the other hand, sound scattering through tissues is two to three orders of magnitude less 
than optical levels. As a result, the depth limit for PA imaging becomes the hard limit of light 
diffusion. Given that electromagnetic radiation can reach the target and absorb the energy, the PA 
signal can be generated and detected. The PA signal strength is then proportional to the extinction 
coefficient and the magnitude of optical fluence delivered to the location. The image resolution 
can be tuned using ultrasound frequency, but the limit is approximately 1/200 of the imaging depth. 
For example, an image collected at 2 cm would have a maximum resolution of 100 µm.41 During 
image collection, the instrument uses bursts of laser light to generate ultrasonic waves. The basic 
instrumentation required for signal collection is (1) radiation source—laser or monochromator 
capable of being pulsed at 50-1200 Hz, (2) sample cell—capable of holding sample in a water bath, 
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(3) detector—pending on sample for analysis, can be ultrasound transducers or microphone, and 
(4) image reconstruction—converts the raw data into usable three-dimensional image.  
 
Photoacoustic Development 
Although the photoacoustic phenomenon has been known for over a hundred years, the 
expansion into the imaging field has not occurred until the past decade. A contributing reason to 
the slow development is due to the lack technological support for PA imaging. Similar to other 
three-dimensional biomedical imaging platforms, PA data collection and processing requires 
significant computational resources. Significant research into developing both the software and 
hardware was required before PA imaging could be applied to probe biological problems. Within 
the current field of PA imaging there are three subsets of imaging technology (1) focused-scanning 
photoacoustic microscopy (PAM), (2) photoacoustic computed tomography (PACT), and (3) 
photoacoustic endoscopy (PAE).42 These forms of PA imaging deviate in the method of how the 
laser is focused onto the sample, which also changes the potential depth and resolution.  
PAM was developed by Lihong Wang as the first demonstration of how PA imaging 
technology can break the optical limit. PAM utilizes a point-by-point detection and raster scanning 
technique over an object to render an image. PAM instruments can be adapted from traditional 
confocal or fluorescence microscopes. Since these types of microscopes are already equipped with 
excitation laser, the major addition to the set up would be the incorporation of an ultrasound 
transducer to collect the PA signal (Figure 2.2).43 During an imaging session, both the optical 
excitation and the ultrasound transducers are focused to maximize signal sensitivity and resolution. 
The PA image is generated by collection of 1D images and the second dimension is calculated-
based on the length of time to detect the ultrasound emission. As a result, the typical resolution of 
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PAM is 5 – 150 µm with a depth penetration of 0.7 – 3 mm.41 PAM reduces depth penetration to 
achieve high resolution, the acoustic center frequency is at least 300 MHz in order to capture higher 
resolution images. However, at even higher frequencies, the signal has greater attenuation by the 
surrounding tissue.42 Despite not having high depth penetration, PAM has the resolution capable 
of capturing vascular systems in fine detail.44 
PACT systems use a full-field illumination rather than the point setting employed in the 
PAM system. In order to accelerate acquisitions times, PACT systems have ultrasonic array 
detectors. PA images are then captured by a full field excitation and reconstruction of the PA signal 
collected by the array. The array system improves the depth penetration and imaging speed; 
however, because the PA emission is collected at once, the data collected must be reconstructed 
into usable images with inverse-algorithms. Different ultrasonic arrays have been developed to 
increase the resolution and imaging for certain samples; arrays have been designed with multiple 
shapes, such as linear, circular or quarter-circle.45 The linear array PACT was adapted to create a 
microscopic PACT system. The linear array has also been incorporated into clinical ultrasound 
imaging systems to convert these instruments into a PA tomographer. The PACT system equipped 
with a linear array can image with resolutions up to 1 mm laterally and 400 µm in the axial 
direction and at depths deeper than 3 mm.46 Circular array PACT is optimized for imaging of round 
shaped samples, such as the brains of animals. The ultrasonic array encircles the sample so that 
any PA signal generated is detected and reconstituted. The images generated do not have any 
missing boundaries as would be observed with other arrays and is capable of imaging through rat 
skulls to achieve a resolution of 200 µm.47- 48 PACT offers a high-resolution imaging method to 
image depths greater than PAM and at faster imaging rates, up to 50 Hz.49  
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PAE has emerged as a method to access deeper internal structures. PACT has been shown 
to be capable of penetrating and imaging at several centimeters in depth; however, most internal 
organs are housed deeper in the body. PAE was developed to adapt PA imaging into a usable 
clinical setting. The PAE instrument consists of an ultrasonic transducer, a mechanical scanning 
component, and an optical fiber (Figure 2.3).50-51 The PAE offers an opportunity for clinicians to 
not only view the topical appearance of internal organs, but also access vasculature of the 
surrounding tissue, providing invaluable insight to medical professionals.  
The development of proper instrumentation for PA imaging has been integral to its 
application to in vivo imaging. The phenomenon of electromagnetic radiation generating acoustic 
waves has been well established; however, it was only in the 21st century that researchers have 
been able to apply it to molecular imaging. Pioneering research by Lihong Wang and co-workers 
was integral in developing techniques to use PA signal to capture images beyond the optical limit. 
Presently numerous companies have begun to commercialize PA tomographers, spurring 
additional research and discovery for novel uses of PA imaging. 
 
PA Imaging with Endogenous Biomolecules  
In the first applications of PA imaging, endogenous molecules provided the required 
contrast. Every molecule has a unique absorption spectra that can be utilized for selective 
excitation. Vascularization and blood oxygenation have been shown to provide invaluable insight 
into multiple biological processes such as tumor development and vascular angiogenesis. Current 
imaging techniques such as micro-PET, micro-CT, or ultrasound are unable to provide complete 
insight into both blood flow structure and oxygenation.32 Unlike ultrasound, PA imaging is devoid 
of the “speckles” commonly seen in ultrasounds caused by echoes of sound waves through tissue 
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and organs. The strength of the PA signal is proportional to the optical absorption coefficient and 
magnitude of optical excitation; as a result, subcutaneous blood vessels are an excellent system for 
PA imaging. Not only does blood consists of strongly absorbing hemoglobin and oxyhemoglobin, 
it also flows in shallow depths in the dermal layer, facilitating the collection of high contrast blood 
vasculatures images (Figure 2.4).51 Additionally, the unique absorbance profiles of various 
biological molecules facilities usage of sequential optical wavelengths to determine blood oxygen 
saturation.52 Taking advantage of the high absorbance of blood biomolecules, high resolution 
images of animal vascular systems have been collected and studied.53  
The expansion of PA imaging into the biomedical field involved fine-tuning of systems 
and reconstruction algorithms. Before in vivo studies, researchers relied on using live tissue 
prototypes by running capillaries through tissues phantoms and pumping blood through to simulate 
a vascular system.54 Comparison of the PA image collected and the actual set up allowed 
researchers to not only optimize conditions but also understand the resolution capability of PA 
imaging. Given correct initial modeling with simulated representations of live systems, future 
animal work could be undertaken. Beginning in vivo studies of PA imaging on blood started with 
establishing the capability of PA imaging to achieve an imaging frame rate fast enough to monitor 
rapid heat rates of small animals. The PA imaging system was able to accurately monitor up to 
300 beats per minute (bpm) in adolescent mice, demonstrating the first application of real-time PA 
imaging to the study of physiological dynamics.55  
As the technology advances, so does the complexity of animal model systems. 
Neuroscience has relied on functional MRI and PET to image the brain; however, these techniques 
cannot detect different hemoglobin states and intracellular events. Optical imaging has the capacity 
to sense these events, but pure optical imaging has been unable to be applied to the brain due to 
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poor spatial resolution. PA tomography can overcome the disadvantages of both pure optical 
imaging and pure ultrasound imaging. PA images of rat brains using 532 nm excitation light that 
delivered an incident energy density <10 mJ/cm2, with a circular array ultrasonic transducer with 
a focal diameter of approximately 1 mm were collected. After collection of the transcranial PA 
image, the rats were sacrificed and operated on to expose the tissue imaged. Due to the different 
optical absorption of brain tissue, the anatomical structures have high contrast with a spatial 
resolution of 0.2 mm (Figure 2.5).56 Wang and co-workers also demonstrated that PA tomography 
can non-invasively image neural activity.  For instance, blood flow increases in response to 
increased neural activity, this effect can be imitated through whisker stimulation in rats.57 This 
effect is discernable by the comparison of PA images (Figure 2.5). The ability to collect high 
resolution images of blood flow facilitates the application of PA tomography into studying the 
microvasculature of various model to diagnose vascular conditions.  
Outside of structural assessment, PA imaging has been applied to studying simultaneous 
functional and molecular microenvironments.  Irradiation of nude mice brains implanted with 
human glioblastoma tumor cells at 764, 784, 804, and 824 nm provided enough data to plot the 
spectral distribution of oxyhemoglobin and deoxyhemoglobin. PA images showed the presence of 
a hypoxic region that corroborated with the image taken probing for integrin overexpression.58 PA 
tomography has also been applied to angiogenesis-associated studies to visualize various tumor 
models.59-60 PA images have the resolution required to resolve the hypoxic environments and the 
altered vasculature structure. PA tomography of human breast tissue has provided a diagnostic 
breast cancer tool that has proven more accurate than X-ray mammography for malignant tumor 
detection. The tumor microvasculature has increased angiogenesis, resulting in higher contrast 
over surrounding tissue. During a study in 2009, researchers found that PA tomography could 
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detect 18 out of 20 malignant tumors samples, while X-ray mammography was only able to 
identify 14.61-62 
Considered as the most deadly of the skin cancers, melanoma is treatable with early 
detection. Melanin, the light absorbing molecule in melanosomes have greater absorption than 
blood and water at 700 nm, providing the high contrast required for deep tissue imaging.63-64  
Handheld PA microscopy has been developed for detection of melanomas and has improved 
penetration depth over other non-invasive imaging techniques, providing another important 
clinical application for PA imaging. 65 Water has the greatest absorption in tissue at 920 to 1040 
nm, facilitating its selective detection in biological tissue.66 Cerebral edemas occurs when the 
blood brain barrier is weakened and intravascular fluids can penetrate into the cerebral 
extracellular space, resulting in tissue swelling.67 Cerebral edemas can be caused by a variety of 
events such as head trauma, strokes, or tumors. PA tomography can detect and monitor the 
progression of induced cerebral edemas by imaging water in the brain to provide insight into the 
biological events during and after cerebral edemas.68 
 
Exogenous Contrast Agents 
The prolific and unique absorption characteristics of endogenous biomolecules facilitates 
label-free imaging by reliance on intrinsic molecules for contrast. However, application of 
exogenous contrast agents provide a means to further expand the applications of PA tomography. 
Intrinsic biomolecules strongly absorb in the visible spectrum, causing higher optical absorption 
and scattering when using excitation in this range. As a result, usage of these wavelengths limits 
the depth of PA imaging due to reduced light penetration. To access deeper tissue, the excitation 
wavelength must have minimal scattering and absorption by biological tissue, characteristic of the 
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near-infrared window (Figure 2.4). From 650-900 nm there is minimum absorption by 
biomolecules, indicating that NIR light will have reduced scattering and enhanced penetration. As 
a result, development of NIR PA contrast agents are vital to advancing this imaging technology. 
Currently, the main exogenous contrast agents employed are fluorescent molecules and 
nanoparticles.  
 Presently, only a few organic fluorescent molecules have been used for PA imaging. For 
instance, indocyanine green (ICG) is a non-toxic and water soluble NIR dye with an optical 
absorbance of 790 nm. ICG also is weakly fluorescent in water, less than 1%, which facilitates 
dual contrast ability for both fluorescence imaging and PA imaging.69-70 In comparison to 
endogenous contrast, ICG extends the imaging depth from 2.6 cm to 5.2 cm .71-72 Incorporation of 
the ICG to single walled carbon nanotubes increases the PA signal by 300-fold; however 
cytotoxicity has been an issue due to aggregation in the liver .73 ICG has been found to localize in 
certain tumors types to act as a contrast agent; however, conjugation with peptides increases the 
affinity of ICG to tumor cell lines.74 ICG has also been conjugated to an anti-clonal antibody for 
human epidermal growth factor (EGFR) to aid in the determination of target-specific incorporation 
of the antibody.75 However, a limitation of ICG is due to the difficultly in functionalization for 
labeling; as a result, an ICG derivative, IRDye-800, has be developed and more widely employed 
for protein and antibody labeling.76 
 Nanoparticles have been studied extensively due to their potential application in the 
biomedical field. Nanoparticles have been applied to delivering, targeting, and visualizing various 
biological targets. PA tomography has been implementing gold nanoparticles to target and act as 
exogenous contrast agents for molecular imaging. Gold-based nanoparticles have excellent 
biocompatibility, excellent functionalization capability, and tunable size and shape.77 Because of 
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the adaptability of nanoparticles, PA tomography has used a variety of gold nanoparticle shapes 
for imaging. Gold nanocages have strong optical absorption in the NIR region and tend to 
accumulate in tumor regions due to the enhanced permeability and retention effect (EPR effect).78 
Injection into rat subjects resulted in an 81% increase in optical absorption in the cerebral cortex.79 
Similarly, gold nanoshells have been employed to increase PA signal in the rat brain cortex. The 
nanoshell nanoparticle consists of a silica core encapsulated by a thin metal layer, the adjustment 
of core size to shell thickness changes the optical resonance. The optimization of a gold nanoshell 
for PA imaging resulted in a 63% enhancement of the optical absorption in rat brains.80 The 
nanoshell was found to be less compatible to nanocages due to their larger size, > 100 nm for 
nanoshell to < 50 nm in nanocages. 
 An additional gold nanostructure that has gained traction are gold nanorods. Previous 
studies have shown that certain malignant cells lines uptake more gold nanorods, which can then 
be targeted and irradiated at 800 nm to result in cell death. These properties suggests that PA 
contrast agents can also be used for photodynamic therapy.81 Gold nanorods also have stronger 
optical absorption over nanoshells and can be made much smaller, on average 50 nm x 15 nm. 
Even at the low concentrations of 1.25 pM gold nanorods, there is still a contrast enhancement.82 
Conjugation of gold nanorods with EGFR resulted in a greater contrast increase in the tumor region 
over gold nanorods alone.83 Gold nanospheres are hollow spheres approximately 40 nm in 
diameter. When conjugated with thiolate polyethylene glycol moieties, the nanospheres also 
demonstrate contrast enhancement and improved distribution and elimination half-lives of 1.38 
and 71.82 hours, respectively.84 Gold nanobeacons are colloidal nanoparticles with a phospholipid 
surfactant encapsulating a gold oleate particle. Conjugation of nanobeacon and αvβ3-
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peptidomimetic antagonist, enables nanobeacons to selectively accumulate with immature 
neovasulature, providing a method to quantify angiogenesis in vivo.85 
Outside of gold nanostructures, single-walled carbon nanotubes (SWNT) have been shown 
to have excellent applicability to PA tomography. In comparison to other contrast agents, SWNTs 
have enhanced disease targeting ability and a six-fold signal enhancement in PA signal at 1064 nm 
irradiation.86-87 SWNT have also shown affinity to accumulate in lymph nodes over surrounding 
blood vessels. The higher optical absorbance of SWNT over endogenous biomolecules provides a 
unique approach to lymph node mapping. Sentinel lymph node biopsy is currently the standard 
treatment of node-negative breast cancer, usage of SWNT can aid in identifying sentinel lymph 
nodes to provide a treatment option without requiring continual biopsies 88 SWNT has also been 
found to selectively target cancer cells and induce cell death through a photoacoustic explosion.89 
SWNT conjugated with folate molecules facilitated an increased uptake in cancer cells through a 
folate-folate receptor-mediated pathway. The SWNT destructive pathway is not caused by a 
temperature change, but rather through a large photoacoustic effect generated from irradiation by 
1064-nm Q-switched millisecond pulsed laser, resulting in a shock wave that kills the cell. The 
SWNT can be readily conjugated; for example, SWNT coupled with cyclic Arg-Gly-Asp (RGD) 
peptides through polyethylene glycol grafted phospholipids and binds with high affinity to αvβ3 
integrin. The administration of the conjugated SWNT resulted in an eight-fold increase in 
photoacoustic signal within targeted tumors in comparison to non-conjugated SWNT.90  
Recent work has begun to explore PA turn-on contrast agents that, in response to a certain 
event, will result in an increase in the PA contrast. Of note is the use of PA imaging to visualize 
the gene expression of lacZ in vivo. Employing the same techniques as gene expression imaging, 
an exogenous reporter gene of lacZ is incorporated into the genome of the model of interest. Upon 
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incubation with X-gal, a dark blue product is released after glycosidic linkage cleavage by lacZ. 
The modulation in optical absorption acts as a PA contrast agent and can be resolved to 400 µm 
spatial resolution. 91 Protease-sensitive imaging probes have also been developed for PA imaging. 
In the presence of proteases, the imaging probe releases a chlorophyll derivative with a NIR 
absorption.92 Before cleavage, the probe tends to aggregate as dimers or trimers; upon cleavage, 
the probe no longer aggregates and has an altered the absorption profile from that of the cleaved 
product. The shift in absorption results in an a discernable PA signal enhancement over the parent 
probe. These techniques allow PA tomography to image not just molecular structures, but also the 
biological activity. 
Development of high resolution imaging methods to detect and visualize cancers or 
diseased state is a major goal in biomedical sciences. Early detection may lead to better prognosis 
owing to early treatment. PA imaging provides higher resolution than MRI (mm resolution) and 
comparable resolution to PET (mm – µm) without the need to use harmful ionizing radiation. The 
field of PA imaging is quickly growing as the PA tomographers and microscopes become more 
and more widespread. PA imaging is able to break through the optical limit of imaging and yet 
retain the ability to image for activity and with high resolution.  With the development of 
ultrasound detection and optimization, the collection of PA images has increased in resolution and 
depth. The hybrid imaging nature of photoacoustics allows for endogenous absorbers, which 
previously scattered and reduced resolution of optical imaging, to act as contrast agents to visualize 
morphology of vascular systems in vivo. Discovery of exogenous contrast agents for PA imaging 
affords an improved imaging resolution and depth penetration in addition to an ability to image 
for biological activity. However, within exogenous contrasts agents, the majority of current 
methods is accumulation-based. Few examples exist for activity selective PA contrast agents, of 
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which, there has been a lack of PA probes capable of detecting small molecule analytes. As PA 
tomography develops, the deficiency in analyte specific probes must be addressed to facilitate 
further breakthroughs in in vivo molecular imaging.  
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CHAPTER 3 
COPPER IN BIOLOGY1 
 
Biological Copper 
The transition metal, copper, has been shown to be an essential trace element required by 
all organisms for proper biological function.93 Copper is the third-most abundant transition element 
found in the human body. The ubiquitous necessity of copper stems from its ability to form two 
redox states, Cu(I) and Cu(II). The dual redox states allows copper to function as catalytic cofactor 
in redox chemistry for a variety of biological pathways.93  Several key enzymes require copper for 
activity, such as cytochrome c oxidase, lysyl oxidase, and superoxide dismutase (SOD), to name 
a few.94 These enzymes have important roles in energy regulation and protection against reactive 
oxygen species. Copper is obtained through dietary consumption, its absorption is strictly 
regulated in the small intestine and delivered to the liver for allocation to endogenous enzymes or 
elimination in bile. In particular, regulation of copper concentrations occurs through biliary 
excretion; when consumption is high, absorption of copper from dietary sources decreases.95 
Misregulation of copper pathways results in numerous lethal disorders. 
Unbound copper is maintained in low to nonexistent concentrations within cells. 
Researchers estimate the upper limit to free copper to be 10-18 M, roughly one atom of copper per 
cell.96 Metallochaperones control the uptake of copper into cells and the transfer of copper between 
target molecules.93 Peptides are an effective chelator of numerous metal ions with high specificity 
for certain metals. Cu(II) ligands in general form 3N or 4N coordination to the metal ion, where 
                                                          
1 This chapter includes data and results previously published in the Journal of the American Chemical Society. 
Zhang P, Li H, Smaga LP, Hoffman RA, Chan J. “Photoacoustic probes for ratiometric imaging of copper(II).” 
JACS. 2015, 137, 15628-15631. 
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each N represents a coordination site between the peptide chain and the ion. Most often, it is the 
nitrogen backbone that acts as the N-donor that coordinates to the copper ion.97 Most common 
copper complexes contain oligopeptide sequences that undergo metal promoted conformational 
organization.98 For example, the pentapeptide sequence, Asn-Ser-Phe-Arg-Tyr (NSFRY), when 
complexed with copper has a stability increase of over 5-fold.99 The significant increase in stability 
arises from the favorable interactions between amino acid side chains. 
The average human body contains less than 110 mg of copper; if unbound, the copper is 
too redox reactive and causes oxidative damage throughout the system. Metallochaperones are 
necessary to ensure the endogenous copper is both bound and trafficked to facilitate proper cellular 
function.100 Mutations that affect the metallochaperones prevent proper regulation of copper and 
ultimately has been shown to contribute to multiple neurodegenerative conditions. There are three 
primary metallochaperone systems that are responsible for delivery of copper to its target system. 
The first system is Cox17 which delivers copper to the mitochondria, the second delivers copper 
to SOD in the cytoplasm, and finally the last system is responsible for delivery of copper to the 
trans-Golgi network.101 Amyotrophic lateral sclerosis (ALS) has been linked to mutations in the 
Cox17 enzyme and SOD1 enzymes and both Wilson’s and Menkes disease are linked to mutations 
in copper transporting ATPases. Neuorodegenerative diseases such as Alzheimer’s disease (AD) 
and Parkinson’s disease (PD) are associated with misregulation of copper. 
 
Mutations of SOD 
ALS is a delayed onset degenerative disease characterized by death of motor neurons, 
resulting in gradual loss of muscular function and death by respiratory paralysis within 3-5 years 
of symptom onset.102 Typically 1 in 100,000 people are affected by the disease, of those affected 
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approximately 10 to 15% are diagnosed with the familial form of ALS. Approximately 20% of 
those diagnosed with familial ALS have a mutation in the gene sequence for SOD1.103-104 SOD is 
responsible for catalyzing the reaction of superoxide free radical anions into hydrogen peroxide 
and oxygen using copper as a cofactor (1).101 
2𝑂2 ·
−+ 2𝐻+ → 𝑂2 +  𝐻2𝑂2 
(Eq 3.1) 
Animal models with an analogous SOD1 enzyme were shown to have increased levels of 
radical generation. Mice expressing the mutated SOD strain also showed signs of denervation and 
paralysis, comparable to ALS symptoms. However, mice without the SOD1 gene do not develop 
ALS-like symptoms, supporting the conclusion that SOD1 causes a toxic gain of function. 
Researchers found SOD1 had increased catalytic activity, outside of catalyzing the 
disproportionation of superoxide, SOD1 also modifies other substrates, resulting in increased 
cellular levels of toxic radicals.104-105 By specifically targeting the SOD1 pathway and altering the 
concentration of copper, researchers have shown promising therapeutic potential for treatment of 
familial ALS.106 
 
ATPase Mutation 
Cu-ATPases are responsible for trafficking copper to various cupro-proteins and for 
effluxing excess copper. ATP7A and ATP7B are key enzymes in the flow of cellular copper. 
ATP7A is a membrane protein responsible for uptake of copper and the transportation from the 
golgi apparatus to the cell membrane. ATP7A mediates the flow of copper from organ system to 
organ system, ensuring copper homeostasis is maintained (Figure 3.1). Menkes disease is an X-
linked recessive trait characterized by copper deficiency, abnormal kinks in hair structure, and 
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developmental delays caused by undeveloped central nervous system.107 This disease has been 
linked to a mutation on the ATP7A encoding gene, resulting in reduced activity of the enzyme and 
low intracellular copper concentration. The mutated ATP7A is unable to effectively transport 
copper from the intestinal cells to the rest of the body.108 As a result, inadequate amounts of copper 
cross the blood brain barrier to serve as a cofactor in the biosynthesis of important molecules such 
as keratin, myelin, and collagen. Even with copper supplements, the symptoms are not abated. The 
copper becomes trapped in the cytosol and unable to be transported to the target cuproenzymes by 
ATP7A.94 
Wilson’s disease is an autosomal recessive disorder also caused by a mutation within the 
Cu-ATPase family. Contrary to Menkes disease, those affected by Wilson’s disease are unable to 
properly excrete copper. As a result, copper accumulates in organs such as the liver and brain, 
resulting in hepatic and neurological disorders. ATP7B is believed to be a major contributor to the 
onset of Wilson’s disease. After copper is absorbed in the intestine by ATP7A it is delivered to 
hepatocytes, redistributed to various intracellular locations, and cytosolic copper is then 
incorporated to the ceruloplasmin through ATP7B.109 In healthy cells, ATP7B begins to package 
excess copper into the lysosome and bile for elimination (Figure 3.2). Wilson’s disease prevents 
the proper excretion of copper because of a mutation on the ATP7B gene. Researchers have also 
linked lack of ceruloplasmin excretion to contribute to the Wilson’s disease phenotype.110-111 
Given early diagnosis, Wilson’s disease can be treated using copper chelators to prevent over-
absorption of dietary copper as well as liver transplants to replace cirrhotic tissue.  
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Copper Mediated Oxidative Damage 
Other than mutations in copper carrying proteins, deviation in copper concentration or 
coordination to other proteins can lead to other disease states. The redox potential between Cu(I) 
and Cu(II) states enables it to act as an important cofactor in many biological pathways. However, 
given how reactive the copper states are, its presence in the brain can lead to formation of protein 
aggregates and damage surrounding tissue. Copper is an essential element in biological function, 
as seen in Menkes disease, where one of the symptoms of low copper uptake is delayed 
development. Alzheimer’s disease is a progressive neurological disease that effects approximately 
40% of adults over 85 years old.112 One of the hypothesis of the cause of Alzheimer’s is the excess 
production of amyloid precursor protein (APP) that aggregates and eventually forms amyloid 
plaques (Aβ) that cause cell death and dysfunction of neuronal tissue.113-114 The effect copper has 
on the disease is complex and has yet to be completely elucidated. However, it is postulated that 
copper ions induce aggregation of Aβ and causes a release of reactive oxygen species. Aβ plaques 
have a high concentration of copper and other metal ions, suggesting the role of copper in inducing 
aggregation.115 Additionally, interaction between APP and Cu(II) induces an oxidation of a 
cysteine residue as the copper is reduced to Cu(I), this electron transfer reaction is shown to 
enhance formation of hydroxyl radicals.116 The produced radicals can then react with surrounding 
lipids and potentially induce neurotoxicity. 
Many other neurological disorders have also been linked to copper binding and 
perturbation, examples include Prion disease and Huntington’s disease. Prion disease is caused by 
formation of plaques of protease-resistant prion proteins. Studies have found that copper binding 
facilitates the transition of prion protein into the protease-resistant form.117-118 The chelation of 
copper by an outside agent has shown to slow the disease progression. However, chelation of 
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cellular copper does have secondary effects on other biological processes, and cannot serve as a 
viable treatment option. Huntington’s disease is a late onset neurological disease caused by 
neuronal loss in the striatum of the brain, current therapeutics attempt to delay the onset and spread 
of the disease. The link between copper and Huntington’s disease still requires additional 
elucidation; however, there have been studies that have found high copper concentrations in the 
striata of afflicted patients.119 Copper interactions with huntingtin, the main pathological protein 
involved in Huntington’s, has shown to be important in the pathogenesis of the disease. Given the 
important role copper has in multiple neurological diseases, it becomes vital to be able to monitor 
copper in vivo in order to provide insight in how this transition metal effects biological systems. 
 
Copper Imaging 
The vital role copper plays in biological systems has led to the development of methods to 
monitor its metabolism and role has been ongoing since the 1940s. Initial studies on copper 
metabolism used radioisotope tracers on animal models. Of the seven copper radioisotopes, Cu64 
and Cu67 have the longest half-lives of 12.8 and 58.5 hours, respectively.120 Long term studies 
using radioisotopes is not feasible due to short half-lives; additionally, the exposure to radioactivity 
and difficulty in isolating the isotopes also prevents usage of radioisotopes as a common analytical 
tool. Stable isotopes of copper are attractive in performing metabolic studies since there is no 
radiation produced; Cu65 has been used to study copper intake in human and mice studies.121 
Control of dietary consumption of copper ensures that the only copper source in the subjects is 
from the injected Cu65. Researchers used magnetic-sector thermal ionization mass spectrometry to 
measure the ratio of copper isotopes to determine how the body responds to changes in dietary 
copper consumption. Stable copper isotope studies have been mostly limited to animal models and 
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has focused on kinetics of copper metabolism.122 Further studies on sensing copper alone are 
restricted by its low concentration and the natural abundance of 60.2 % Cu 63 while Cu 65 has an 
abundance of 30.8%. 
Another established analytical technique for determination of trace elements in tissue is the 
usage of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Biological 
tissue is prepared as thin slices and measured using line scanning ablation, which can then be 
reconstituted as an image to visualize the distribution of trace elements (Figure 3.3).123 This 
technique provides a highly detailed images of local metal concentrations; however, this technique 
is limited as the sample analyzed is destroyed, preventing in vivo applications. Additionally, 
samples require an internal standard to calibrate between slices which adds to the complexity of 
data collection.124 Despite the in vivo limitations, the LA-ICP-MS still serves as a useful diagnostic 
tool to copper ion distribution. 
Due to the destructive nature of LA-ICP-MS, it is unsuitable for in vivo studies. However, 
X-ray fluorescence microscopy (XFM) is a non-destructive analytical method of high resolution 
mapping of elements. XFM measures the incident X-ray energy across the absorption edge of a 
metal to determine its oxidation state and coordination energy.125 As a result, selective excitation 
of specific metals allows for high-sensitive mapping of concentrations (Figure 3.4). Unlike probes, 
metals are directly images rather than their interactions with exogenous molecules. Recent 
technological advances has improved focus of the X-rays to facilitate sensitive detection of trace 
elements to detect metals in the range of 5.0×10-20 and 3.9×10-19 mol µm-2 with spatial resolution 
in the submicron range.126 XFM has been applied in conjunction with other techniques to image 
tissue for copper analysis. Because of its high spatial resolution XFM studies of tumor tissue 
samples has been able to confirm the presence of labile copper pools in the mitochondria and Golgi 
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apparatus.127 In addition, XFM can aid in functional studies of copper through observation on 
concentration variance in different cell lines and diseased states.128-129 Despite being non-
destructive, XFM still requires frozen or fixed samples for analysis and is unsuitable for in vivo 
studies.  
 
Copper Chemosensors 
Given the vital role of copper and the importance in being able to monitor it in vivo, there 
has been a strong push in the development of chemosensors for copper. Chemosensors describe a 
small-molecule that undergoes a signal change in the presence of an analyte. Fluorescent 
chemosensors are advantageous over other methods due to their ability to be monitored in real 
time and facile detection using optical techniques. The fluorescent chemosensors focused on the 
selective detection of copper employ either a reaction-based or chelation-based approach. Reaction 
-based chemosensors undergo an irreversible chemical reaction in the presence of copper; while 
the chelation approach is based on the selective coordination of Cu(I) or Cu(II) to induce a signal 
change. Similar to copper binding proteins, chelation-based copper chemosensors retain similar 
binding motifs. However, due to the paramagnetic properties of copper, it is a free radical quencher. 
As a result, coordination with copper for the chelation-based chemosensors often resulted in a 
fluorescent turn-off response (Figure 3.5). Without Cu(II) coordination both compounds 3 and 4 
are fluorescent, upon chelation of copper, these probes have almost a completely quenched 
fluorescence.130-131 Turn-off chemosensors are not desirable due to the difficulty in attributing 
responses to solely analyte coordination. Fluorescent chemosensors are liable to photobleach or 
wash out of cells; therefore, loss of signal is not necessarily indicative of analyte detection. 
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 Copper chemosensors that transition from the closed to open spirolactam ring of 
rhodamine and fluorescein-based dyes can overcome the fluorescence turn-off effect.132 In the 
closed ring form, these fluorescent platforms are essentially non-fluorescent. The chelation of 
Cu(II) to 5 redistributes the electron density and causes the lactam ring to open. This transition 
causes an extension of the chromophore conjugation that is characterize by formation of a new 
absorbance band at 529 nm with a 32-fold fluorescence increase. Copper chelating chemosensors 
are reversible probes capable of monitoring real-time concentration changes in vitro. If the binding 
constant, Ka, between the chemosensor and copper is within the biological concentration of copper, 
the chemosensor will turn on and off to indicate fluctuations of copper. 
Reaction-based chemosensors undergo an irreversible reaction that causes an increase in 
fluorescence emission. As a strong Lewis acid, copper is often used as a catalyst to activate certain 
functional groups. Reaction-based copper chemosensors take advantage of this unique catalytic 
ability. Coordination with copper can facilitate cleavage of the latent chemosensor, releasing the 
chromophore from the copper labile component. Since copper facilitates the cleavage of a part of 
the chemosensor, the paramagnetic characteristic of copper does not quench fluorescence of the 
chromophore because after cleavage it freely dissociates. These types of reactions are entropically 
favored and water soluble reactions using copper catalyst have been previously reported.133 
Outside of cleavage-based reactions, copper can also catalyze cyclization reactions that result in 
fluorescence turn-on.134-135 The aniline precursor 6 and 7 undergoes an rapid oxidative cyclization 
to form the fluorescent benzotriazole (Figure 3.6). After cyclization, the fluorescence intensity 
increases over 80-fold but in both chemosensors the absorbance profile undergoes a blue shift, 
which is undesirable for biological applications. 
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Copper also readily catalyzes the hydrolysis of ester and ether linkages. The coordination 
of copper facilitates the nucleophilic attack of water to hydrolyze these bonds. The coordination 
center on the chemosensor provides the ion selectivity. Despite the dominant oxidative state of 
copper to be in the +1 state in highly reducing cellular environments, the majority of reaction-
based chemosensors are for the Cu(II) state. Under physiological reducing environments, both 
compounds 8 and 9 are coupled with a tetradente moiety that exhibits Cu(I) selective reactivity.136-
137 Cu(I) mediates the cleavage of the tetradente ligand and releases 3’-O-methylfluorescein, 8’, 
and induces a >1500-fold in observed fluorescence. For compound 9, the cleavage of the benzyl 
ether results in a ratiometeric fluorescence increase at 472 nm and a decrease at the 420 nm 
fluorescence emission. Ratiometric fluorescence chemosensors have greater accuracy over turn-
on probes since there can be a comparison between two wavelengths to normalize for factors such 
as photobleaching, dye efflux, and probe loading variations. Picolinic esters have been shown to 
chelate Cu(II) selectively over Cu(I).138 Cu(II) coordinates to the ester and nitrogen that facilitates 
the subsequent hydrolysis to form fluorescein (10’), resulting in a dramatic fluorescence turn-on 
(Figure 3.7). The picolinic ester also has been shown to retain reactivity with copper complexes in 
addition to free copper ions.  
 
Application of Photoacoustic Technology 
Fluorescent copper probes provide an excellent option for real-time bioimaging. However, 
despite the selectivity and excellent kinetics demonstrated by various copper chemosensors, there 
is a limitation on the applicability of these probes to multicellular systems, such as tissues or live 
organisms. The fluorescent-based probes are unable to retain their resolution beyond a depth of 
one millimeter. Due to the multitude of biomolecules, such as hemoglobin, water, and proteins 
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present in tissues, light is both scattered and absorbed, reducing the efficacy fluorescent emissions. 
Even with high Φf, the emitted fluorescence will quickly be scattered by the biological tissue. In 
cellular cultures, the light scattering does not significantly impact the readout, but in order to gain 
greater understanding the biological role of copper, studies of copper in multicellular settings 
becomes desirable. Despite efforts toward optimization of Φf and NIR absorbance, fluorescence-
based molecular imaging is cannot break the optical limit of depth penetration. Photoacousitic 
imaging has been shown to be capable of breaking the optical imaging depth and produce high 
resolution images in the centimeter range. 
The current field of PA imaging has only a few examples of small molecule-based analyte 
specific probes. In order to enhance resolution, accumulation-based contrast agents have been 
designed specifically for application to PA imaging. However, these agents rely on passive 
diffusion and are only meant to increase resolution rather than probe into cellular activity. Design 
of analyte specific probes on NIR PA chromophores have two main strategies one is to have a 
drastic absorbance shift, the others is a fluorescence decrease upon analyte interaction (Figure 3.8). 
The PA signal can be simplified into the following equation, 
𝑃𝐴 𝑆𝑖𝑔𝑛𝑎𝑙 = 𝜀 × 
1
1 − Φ𝑓
 
(Eq. 3.2) 
where the signal is proportional to the extinction coefficient (ε) and inversely proportional to the 
quantum yield (Φf).  Upon cleavage of the analyte labile functional group, there would be a 
dramatic bathochromic shift for strategy one, which can be detected as an increasing separate PA 
signal while the signal at the capped molecule’s absorbance will have a decrease in PA signal. In 
the other strategy, the parent capped molecule has a week PA signal due to a high quantum yield, 
but upon cleavage there is a dramatic quenching of fluorescence and increase in PA signal. 
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However, since NIR chromophores generally do not have quantum yields greater than 0.4, the 
signal increase is limited by the initial lower quantum yield. The current project uses the strategy 
of a bathochromic absorbance shift to generate a PA signal. Previous results showed the 
absorbance strategy has a greater PA signal generation in comparison to platforms using the 
quenching of fluorescence method. 
NIR light maximizes depth penetration due to its low absorption and scattering by tissue. 
As a result, the PA probe scaffold requires an NIR absorbance and can undergo a large absorbance 
shift, through review of the literature, the aza-BODIPY platform is capable of fulfilling the PA 
probe requirements. Previous research had shown the deprotonation of a para-phenol caused a 
large red shift in absorbance between the phenoxide (12) and phenol (11) states. (Figure 3.9).29 
The phenol form is analogous to the absorbance profile if the phenol is capped with an analyte 
trigger (13). In the presence of a specific analogue, 13 would be uncapped to form the red-shifted 
12. Physiological conditions are characterized by a pH of 7.4, consequently, the apparent pKa of 
phenol should be lower than 7.4 to ensure formation of only 12 in order to maximize the PA signal.  
Additionally, compound 12 not only experiences a red shift in absorbance from 668 to 734 nm but 
also a concomitant loss of fluorescence. Based on these photophysical properties, further 
optimized 11 can prove to be an excellent photoacoustic probe platform. 
 
pKa Tuning 
The work by Jokic and co-workers demonstrated that the pKa of the aza-BODIPY scaffold 
can be tuned by incorporation of additional electronegative atoms adjacent to the phenol. Based 
on Pauling’s electronegativity scale, fluorine atoms are considered to be the most electronegative 
element.139 Since the initial aza-BODIPY, 11, had a pKa close to physiological pH, the 
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replacement of the chlorine with the more electronegative fluorine atom should result in a decrease 
in the phenol pKa. Synthesis of a mono-fluoro aza-BODIPY was completed using method b of the 
aza-BODIPY synthesis (Figure 3.10). However, calculation of the apparent pKa of 20 indicates 
that the incorporation of the fluoro group did not lower the pKa (Figure 3.11). This observation is 
further affirmed by a comparison of the pKas of the parent phenol analogues. 2-Fluorophenol has 
a pKa of 8.73 while 2-chlorophenol is 8.45; despite being more electronegative, the fluorine atom 
does not decrease the pKa.140   
To achieve the lowered pKa, additional electronegative substituents had to be incorporated 
into the aza-BODIPY scaffold. The substitution of di-ortho halogens lowers the pKa of the phenol 
below the physiological pH, 2-6-dichlorophenol has pKa of 6.79. Given the low pKa of 2,6-
dichlorophenol, incorporation into the aza-BODIPY platform should also decrease the pKa into 
the required range. The dichloro analogue was synthesized using the same synthetic pathway was 
the ortho-fluoro chromophore (Figure 3.10). The phenol was acetylated and underwent a Fries 
rearrangement reaction to form the acetophenone intermediate (22). Under basic conditions the 
chalcone was formed and underwent a 1, 4-Michael addition with nitromethane to form the pH 
sensitive portion of the aza-BODIPY (24). Synthesis of the unsubstituted portion was isolated in 
two steps from benzaldehyde and acetophenone to form compound 15. Upon formation of the final 
product the apparent pKa of 26 was lower than physiological pH at approximately 5.6 (Figure 
3.11). The low pKa ensured that when the scaffold is uncapped the resultant product will be the 
red-shifted phenoxide. Synthesis of the dibromo phenol (32) further enforces the pKa trend of 
phenols can be applied to the apparent pKa of the aza-BODIPY analogue. 
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Solubility 
The low apparent pKa of the aza-BODIPY ensures that at the physiological pH of 7.4, the 
chromophore is in the phenoxide form. However, one of the major drawback of the aza-BODIPY 
system is the poor solubility in aqueous solution. The pH profile of the substituted aza-BODIPY 
required ethanol as an organic co-solvent. Without the ethanol to solubilize the chromophore, 
aggregates form and the sharp absorbance curves are replaced with a broad profile. Comparison 
of the absorbance profile at acidic and basic pHs show no distinguishable peaks. As a result, 
compound 26 is an impracticable scaffold for future in vivo imaging. The aza-BODIPY should be 
water soluble enough to retain is dual wavelength profile at different pHs without an organic co-
solvent.  
Incorporation of PEG groups has shown to have strong potential in preventing 
aggregation.25 Aza-BODIPY platforms are also amenable to functionalization, PEG groups are 
installed using a SN2 reaction between a phenol and a mono-substituted PEG chain (Figure 3.12). 
Length of the PEG chain as well as number of PEG chains substituted on the molecule are 
correlated with the degree of water solubility. Investigation on the effect of PEG chains for the 
aza-BODIPY solubility were first conducted using mono and di-substitution with diethylene 
glycol units.   
The solubility trend for 37 and 42 indicates that the di-substituted diethylene glycol 
moieties were insufficient in solubilizing the aza-BODIPY enough to prevent aggregation (Figure 
3.13). 37 did not aggregate until the solution reached the ratio of 1:4 EtOH to aqueous buffer. 42, 
with two PEG chains, is soluble in lower percent ethanol solutions, the additional PEG chain 
increases the water solubility enough so that aggregation occurs at 1:9 EtOH to buffer. Without 
normalization, 42 also is noticeably lower in absorbance than 37 despite in equal concentration 
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and conditions. The decrease in extinction coefficient is most likely due to the interactions with 
the ortho-PEG and the aza-BODIPY core. The long PEG chain is potentially preventing the 
chromophore from becoming planar. High extinction coefficient is important in PA imaging; as a 
result, the placement of PEG chains in the ortho position is not a viable substitution position for 
increasing solubility. Additional PEG chains are required to ensure sufficient water solubility.  
The four aryl rings on the aza-BODIPY scaffold are attributed to causing the molecule to 
be non-polar and inherently hydrophobic. A possibility to increase the water solubility is to remove 
non-polar groups as well as introduce polar substituents to the aza-BODIPY core. Previous studies 
indicated a method of synthesizing a truncated version of the classic aza-BODIPY.141 The two aryl 
rings on the 1 and 7 position are replaced with methyl substituents (Figure 1.2). Without the larger 
aryl rings, the truncated version should potentially have enhanced water solubility. Synthesis of 
the truncated version began with an allyl protected 4-bromophenol. Lithium-halogen exchange 
using n-butyl lithium and the subsequent reaction of the lithium adduct with crotonaldyhe 
produced the intermediate benzyl alcohol (47) which was oxidized using 2-iodoxybenzoic acid to 
afford the alpha-beta unsaturated ketone (48). The truncated chalcone underwent 1, 4-Michael 
addition with nitromethane to produce the key nitrobutyrophenone intermediate, 49, that formed 
the aza-BODIPY core under an ammonia acetate and alcohol solution. The final step was BF2 
incorporation with BF3-diethyletherate (Figure 3.14).  
The truncated aza-BODIPY molecule has a similar pH profile compared to the parent 
compound (Figure 3.15).  The inflection in the pH profile is close in value to the full analogue, 
suggesting that the dichloro substituents are required for full deprotonation at physiological pH. 
The solubility profile of the truncated analogue does not have a significant improvement given the 
loss of two aryl rings. 51 still requires at least a 3:7 ethanol to aqueous buffer solution before the 
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absorbance maximum begins to round out. More importantly, the loss of the two aryl rings blue 
shifts the absorbance maximum. The full aza-BODIPY, 26, has an absorbance of 682 nm and a 
red-shifted 729 nm absorbance for the phenoxide form. The solubility of 51 is improved and 
similar in trend as the mono-PEG solubilized 37; however, the absorbance profile of 51 is not NIR 
red-shifted enough for potential ratiometric sensing of analytes. Substitution of electron-donating 
groups in the para position of the right side can potentially increase the absorbance values, but the 
shift will not guarantee both the phenol and phenoxide have absorbance maximum above 680 nm 
and this platform was not pursued further.  
 
Final Platform 
The subsequent target was to increase the number of PEG chains, as well as the number of 
monomeric units on each chain. Substitution in the ortho position reduced the extinction 
coefficient; in order to maximize this parameter, PEG substituents were positioned distant from 
the aza-BODIPY core. In addition to PEG substituents, incorporation of sulfonate groups has also 
been used as a strategy to increase water solubility.20 Other strategies to solubilize the organic 
molecules are similar to strategies to solubilize pharmaceutical drugs. Instead of organic co-
solvents, another strategy for solubilization of organic molecules utilizes surfactants. Cremophor 
EL (CrEL) has been used as a formulation vehicle for poor water-soluble drugs, it has also been 
used as to help solubilize chromophores.143-144 Given these strategies, synthesis of a tri-substituted 
triethylene sulfonate aza-BODIPY was synthesized and characterized (Figure 3.16).  
In order to add the PEG chain, triethylene glycol was reacted with tosyl chloride to isolate 
a mono-tosyl PEG chain. The tosyl group activated the PEG chain for the subsequent nucleophilic 
attack by phenol. Once the PEG chains were appended, the synthesis of the water soluble analogue 
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was conducted in a similar manner as the original 26 synthesis, except for the allyl protection of 
the dichlorophenol. The protection of the 2, 6-dichlorophenol facilitate subsequent purification. 
Protection of the phenol facilitates product separation as well as protects the phenol from possible 
sulfonation in subsequent steps. After dimerization, a crucial TBS-protection on the ethylene 
glycol was required to ensure adequate solubility of the molecule in organic solvents for the BF2 
chelation. Sulfonation of the PEG chains to form 63 increased water solubility over 62 and 
successfully synthesized a stable water soluble aza-BODIPY for usage as a PA probe.  
 
Reaction-based Trigger for Cu(II) 
By capping the dichlorophenol on 21, the chromophore remains in the phenol form and 
only when the anyalyte is present will the molecule react and to undergo the red shift in absorbance. 
Determination of conditions required to couple on an analyte specific trigger was conducted on 
the original unsolubilized 26. The initial assumption was that the phenol was nucleophilic enough 
to use SN2 type reactions to install triggers. The first attempt used a known hydrogen peroxide 
trigger (Figure 3.17). 26 was heated in dry DMF over 3 days; however, the long reaction time did 
not afford satisfactory yields. The reaction only yielded 7% of the final product, the rest was 
recovered as unreacted starting material. The initial assays on trigger cleavage incubated 65 in a 
hydrogen peroxide solution did not result in any change in absorbance profile, despite long 
incubation times at 37°C. The lack of turnover indicates that the trigger was not correctly installed 
or the reaction is trapped at a capped intermediate state.  
 Given the lack of response to H2O2, the synthesis of a copper chemosensor became the 
forefront of concern. For the current detection strategy, the chemosensor requires a reaction-based 
approach. The picolinic ester has been demonstrated as a selective copper sensor. The first attempt 
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for coupling the picolinic ester onto the platform also employed an SN2 type reaction (Figure 3.18). 
However, similar to the boronic ester reaction, the SN2 with the picolinyl chloride also resulted in 
low yields. The low reactivity of the phenoxide was unexpected but can be attributed to the electron 
density donating into the molecule, extending the conjugation and also effectively reducing the 
nucleophilicity. In order to synthesize the final chemosensor in usable quantities, another synthetic 
pathway was required.  
Carboxylic acid coupling has been a prolific research area due to the application in peptide 
synthesis. Rather than usage of an amine to form an amide linkage, the coupling between 
carboxylic acids and hydroxyl groups form an ester linkage. Both N,N-dicyclohexylcarbodiimide 
(DCC) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were used to couple the 
picolinic acid and 26 produces a copper labile ester linkage (Figure 3.19). EDC showed better 
coupling efficiency over DCC and is also a water soluble carboxyl activating agent. Given the 
successful formation of 66, subsequent metal assays were conducted to determine the selectivity 
of the picolinic ester. The water solubilized 64, was insoluble in dichloromethane and required 
water as the solvent for the coupling reaction to form a final water-soluble probe, 67.  
 
Metal Selectivity 
Incubation of 66 and 67 with 50µM Cu(II) resulted in a gradual cleavage of the picolinic 
ester at room temperature (Figure 3.20). 66 shifts from an absorbance maximum of 680 nm to 755 
nm after picolinic ester cleavage. The addition of PEG groups shifts the absorbance maxima of 67 
to 697 nm when capped with picolinic acid and to 767 nm in the phenoxide form. The ratio of the 
uncapped product absorbance to the capped absorbance indicates reaction progression. The >70 
nm absorbance shift between product and reactant facilitates ratiometric application. The 
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ratiometric approach eliminates inconsistencies between samples due to variation from dye 
accumulation or photobleaching. Both probes also have high selectivity for Cu(II) over other 
biologically relevant cations (Figure 3.21). Alkaline earth metals, Mg and Ca, were incubated at a 
higher concentration of 2 mM to mimic biologically relevant concentrations. Since Cu(I) can 
oxidize to Cu(II), the Cu(I) incubation was completed under a reducing environment to prevent 
probe turnover by generated Cu(II).  
 
Photoacoustic Imaging 
Optical data of 26 and 64 indicates favorable characteristics for PA imaging. The aza-
BODIPY Cu(II) chemosensors have a high extinction coefficient and NIR absorbance within the 
680 nm laser line limit for our PA tomography system (Table 3.1). Additionally, both compounds 
are non-fluorescent in aqueous buffer in their phenoxide state. Similar to 11, when the phenoxide 
forms, the fluorescence also decreases, indicating that the photoacoustic signal will increase. In 
order to collect the PA images, samples were loaded into a fluorinated ethylene propylene (FEP) 
tube and inserted into a 1 cm thick phantom that is suspended in a water bath for image collection. 
The phantoms used were made of milk, agarose, and water that was optimized to mimic the light 
scattering properties of biological tissue. The tissue phantom is also important in ensuring the 
excitation light is spread evenly throughout the sample. Sound waves travel four times faster 
through water than air, submerging the sample in a water bath ensures a maximum PA signal. 
The PA tomographer can collect comparable data as optical UV-Vis instruments. The pH 
profile generated using PA signal is comparable to the optical plot (Figure 3.22). The tremendous 
difference between the optical and PA imaging capability to the image at a depth of 1 cm. Figure 
3.22b is the reconstructed image generated from the PA signal. If optical methods were used on 
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the same sample, the fluorescence emission is abolished (Figure 3.22c). The ability of PA imaging 
to provide high resolution images at depths optical imaging cannot reach opens exciting potential 
for molecular imaging. The Cu(II) PA probe synthesized showcases the power that PA imaging 
has at accessing these depths. Given the success of this preliminary work, further development 
will allow for in vivo studies on not just cellular cultures, but also for application into multicellular 
organisms.  
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CHAPTER 4 
FUTURE DIRECTIONS 
 
Copper (II) Sensing 
The field of photoacoustic imaging has quickly developed over the past decade.41 However 
despite the work done in the field, the only method to distinguish between physiological states is 
to rely on endogenous optical absorbers or the use of contrast agents. Endogenous biomolecules 
can distinguish between physiological states, but addition of exogenous molecules increases 
resolution and depth penetration. Currently, the contrast agents employed are small molecule dyes 
and nanomaterials that passively diffuse or are taken up by receptor-mediated pathways. These 
agents increase the contrast between physiological states. However, PA probes that elicit a change 
in absorbance in response to a particular physiological state are more versatile and important in 
measuring the role of an analyte in its native environment without large perturbations to the system 
being studied. In this work, significant effort has been taken to successfully synthesize the first 
ratiometric photoacoustic probe for Cu(II). The copper probe is both selective and water soluble 
with a normalized 100-fold turn-on response. 66 and 67 have shown excellent PA properties in 
vitro, the next step is to test these probes in vivo.  
The advantage of PA imaging over purely optical methods, like fluorescence imaging, is 
its ability to break the optical limit. Due to light scattering induced by biological matter, at depths 
greater that 1 mm, there are too many scattering events that prevent the photon from retaining its 
original incidence angle and is incapable of being focused. To capitalize on the unique properties 
of this imaging method, the subsequent experiments required is to apply 67 to tissue specimen and 
animal models. The application to more complex environments will elucidate if the current design 
43 
 
will be a valid strategy for multicellular systems. Continuation onto animal models provides the 
opportunity for PA tomography to monitor where Cu(II) is localized and begin to investigate its 
misregulation and effect on physiology.  Current studies are applying the Cu(II) probe to begin 
studying copper misregulation in Wilson’s and Menkes disease models.  
 
Additional Platforms 
In order to continue to advance analyte specific PA probes, additional platforms are needed. 
The first strategy used was relying on an absorbance shift caused by the formation of a phenoxide 
on the aza-BODIPY chromophore. The phenol moiety can be coupled with a variety of triggers 
but results indicate that the phenol requires an activating agent, such as EDC, to have high yielding 
results. Thus, only probes with a carboxylic acid handle are viable to coupling conditions. The 
formation of the phenoxide also quenches the fluorescence; however, retention of fluorescence 
facilitates the possibility of bimodal imaging. This quandary has led to the development of other 
aza-BODIPY scaffolds that are susceptible to more mild and diverse coupling conditions. Results 
by Shea and co-workers discovered that the formation of a B-O chelate also shifts the absorbance 
over 80 nm (Figure 4.1).93 The shift is believed to be caused by the interlocked ring increasing the 
dye planarity. The absorbance shift is comparable to the phenol to phenoxide shift, and should 
provide an additional PA turn-on probe strategy.  
Investigation to the viability of this strategy began by using the truncated form of the aza-
BODIPY scaffold (Figure 4.2). In order to install an ortho protected phenol, 3-methoxyphenol was 
selectively brominated and allyl protected to afford compound 68. Subsequent lithium halogen 
exchange with crotonaldehyde forms the benzyl alcohol 79 that is immediately oxidized before 
undergoing a 1, 4-Michael addition with nitromethane as the nucleophile. Refluxing with methanol 
44 
 
and ammonium acetate yields the dimerized product 73, followed by BF2 chelation produces the 
preliminary probe scaffold. Removal of the allyl group simulates the cleavage of the analyte 
specific moiety and tests the viability of this approach for PA imaging.  
 The deprotection of the allyl group results in B-O chelation and was carried out at 40°C 
overnight. Characterization of 74 showed the product undergoes a significant bathochromic shift 
from 637 to 716 nm. Additional work is required to optimize reaction conditions and couple 
analyte specific groups to the scaffold. Preliminary results indicate the truncated aza-BODIPY is 
not red-shifted enough for both capped and uncapped versions to be analyzed using the PA 
tomographer; therefore it was no longer a viable ratiometric probe. Conversion to the full aza-
BODIPY platform ensures the absorbance will be sufficiently red-shifted for ratiometric imaging. 
An additional requirement is to synthesize a water soluble analogue. Similar to the strategy in the 
first probe platform, PEG moieties are appended to the para position (Figure S82). Coupling of 
analyte specific moieties was readily completed using both SN2 and EDC mediated methods. The 
more reactive phenol suggests that the B-O chelate is potentially a more versatile ratiometric PA 
strategy than the dichloro phenol substituted aza-BODIPY. 
As photoacoustic imaging continues to develop, the ability to monitor specific analytes 
becomes an important chemical tool to the scientific community. PA probes which undergo a 
change in signal intensity only in response to certain cellular environments or analytes provide a 
means to interrogate complex biological interactions. PA tomography presents an exciting 
opportunity in the field of non-invasive deep tissue imaging. The successful synthesis of near-
infrared platforms that can be capped with analyte specific triggers facilitates future in vivo studies 
into biological systems. Before scientific breakthroughs on biological interactions can occur, the 
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chemical tools must first be developed. The ratiometric Cu(II) probe is the first successful attempt 
to progress this field of analyte specific small molecule-based probe for PA imaging.  
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FIGURES AND TABLE 
 
 
Figure 1.1. Jablonski diagram depicting possible electronic states and transitions accessible to 
excited electrons. Fluorescence emission only is produced from the S1 and So states while 
vibrational relaxations produce the photoacoustic signal.31  
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Figure 1.2. Representation of the BODIPY core. a) BODIPY core with the IUPAC numbering 
system. b) Replacement of the 8 or meso position with a nitrogen forms the aza-BODIPY core. 
 
 
 
 
 
 
 
 
 
Figure 1.3. Formation of aza-BODIPY core. a) Method one strategy is the condensation of 
substituted pyrroles. b) Method two forms the aza-BODIPY core through dimerization of 
nitrobutyrophenone in the presence of an ammonia source. 
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Figure 1.4. Examples of increased water solubility aza-BODIPY molecules. Introduction of polar 
substituents increases the hydrophilicity of the molecule.24  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. pH sensitive aza-BODIPY. The low pHs the dimethyl aniline is protonated, as the 
pH increases the molecule undergoes a bathochromic shift with each deprotonation step.30 
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Figure 2.1. Process for photoacoustic signal generation.  
 
 
 
 
 
Figure 2.2. Example of dark-field confocal PAM system set up. 42 
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Figure 2.3. Sample PA endoscope apparatus. a) Schematic diagram. GM, geared micromotor; JB, 
jewel bearings; MN, magnets; OF, optical fiber; PM, plastic membrane (imaging window); SM, 
scanning mirror; UST, ultrasonic transducer. b) Photograph of the distal end of the probe with laser 
emitting through the central hole of the transducer. The probe diameter is 4.2 mm.50 
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Figure 2.4. Optical absorbance profile of biologically relevant molecules found in tissue.51 
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Figure 2.5. PA tomography imaging of rat brain. a) PA image of superficial layer of rat brain 
acquired with skin and skull intact. C, cerebellum; H, cerebral hemispheres; O, olfactory bulbs; 
MCA, middle cerebral artery; CS, cruciate sulcus; FT, fissure transverse; V blood vessels. Image 
taken on a 4 cm x 4 cm region. b) Open-skull photograph of rat brain surface. c) Functional imaging 
of cerebral hemodynamic change, PA image of superficial layer of rat brain with skin and skull 
intact in a 2 cm x 2 cm range. d, e) PA image corresponding to left-side and right-side whisker 
stimulation. Image is generated by overlay with image c. f) Photograph of open-skull rate.56 
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Figure 3.1. Copper transport mediated by ATPases. ATP7A is responsible for the absorption of 
dietary copper from the intestinal track. ATP7B regulates to elimination of excess copper. 
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Figure 3.2. Copper transport mediated by ATPases. Closer look at the copper elimination 
pathways regulated by ATP7B. 
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Figure 3.3. Sample processing for LA-ICP-MS. Tissue samples are cryo-cut and mounted on glass 
slides for LA-ICP-MS measurement. 
 
 
 
 
 
 
 
 
73 
 
 
 
 
Figure 3.4. Sample processing X-ray fluorescence microscopy. Samples must be prepared and 
mounted onto glass slides before imaging can begin. 125 
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Figure 3.5. Chelation-based Cu(II) chemosensors. Compounds 3 and 4 undergo a fluorescent turn-
off mechanism of analyte detection. 5 is an example of a fluorescent turn-of chelation-based sensor 
for Cu(II). 130-132 
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Figure 3.6. Cu(II) mediated oxidative cyclization. Upon chelation of Cu(II), compound 6 and 7 
undergo an oxidative cyclization to form a fluorescent benzotriazole. 134-135 
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Figure 3.7. Reaction-based fluorescent copper chemosensors. a) Tris[(2-pyridyl)-methyl]amine 
coordinates to Cu(I) and is cleaved to release the fluorescent coumarin or fluorescein chromophore. 
b) Coordination of Cu(II) to the picolinic ester releases the fluorescent fluorescein dye. 136-138 
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Figure 3.8. PA turn-on strategies. a) Cleavage of reactive group results in a red shift in absorbance. 
b) Fluorescence quenching by cleavage of reactive group results in an increase in PA signal. 
 
 
 
 
Figure 3.9. a) Mechanism of aza-BODIPY deprotonation. b) pH profile spectrum of 11. c) 
Fluorescence profile of 11 shows that 12 is non-fluorescent in a 1:1 ethanol to aqueous buffer 
solution. 
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Figure 3.10. General synthesis of ortho-halogenated aza-BODIPY. 
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Figure 3.11. pH profile of aza-BODIPY. Inflection of the curve represents the apparent pKa of 
the chromophore. The ratio is calculated from the absorbance intensity of the red shifted phenoxide 
to the basic phenol absorbance maximum using a 2:3 EtOH to aqueous buffer.  
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Figure 3.12. Initial solubilization of aza-BODIPY molecule with diethylene glycol functional 
group. 
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Figure 3.13. Solubility profile of PEGylated aza-BODIPY. a) Solubility profile of 37. b) Solubility 
profile of 42. As the ratio of EtOH in solution decreases, the aza-BODIPY aggregates and is seen 
in the absorbance profile as the profile loses absorbance intensity and becomes rounded.  
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Figure 3.14. Synthetic scheme for the synthesis of the truncated aza-BODIPY platform. 
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Figure 3.15. Physical properties of 51. a) pH profile indicates loss of aryl rind does not perturb 
apparent pKa. b) Solubility profile of 51 shows that the solution still needs a high concentration 
of EtOH to prevent aggregation. 
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Figure 3.16. Synthesis of water soluble aza-BODIPY platform. 
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Figure 3.17. SN2 reaction to couple boronic ester trigger onto the parent aza-BODIPY scaffold. 
 
 
Figure 3.18. SN2 reaction to unsuccessfully incorporate the picolinic ester moiety in high yields. 
 
86 
 
 
Figure 3.19. EDC mediated coupling of 2-picolinic acid to the aza-BODIPY. a) EDC mediated 
coupling of picolinic acid with parent aza-BODIPY. b) Coupling of picolinic acid with water 
solubilized aza-BODIPY. 
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Figure 3.20. Time course assay of probe incubation with Cu(II). a) Time course of 2µM 66 in 
ethanol incubated at room temperature with 50 µM Cu(II). Solution was diluted with PBS to form 
a 2:3 ethanol: buffer mixture. b) Time course of 2 µM 67 incubated in PBS at room temperature 
with 50 µM Cu(II). Before measurement solution was treated CrEL to form a 0.1% solution. 
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Figure 3.21. Metal selectivity. a) Absorption turn-on for 2 µM 66 in EtOH calculated from UV-
Vis ratio (UV736/UV653). Mg(II) and Ca(II) were incubated at 2 mM,  50 µM for all other cations 
for 120 min. b) PA turn-on responses for 67 calculated from PA ratios (PA767/PA697). Mg(II) 
and Ca(II) were incubated at 2 mM,  50 µM for all other cations for 90 min. 
 
 
Table 3.1. Photophysical properties of compound 26, 66, 64, and 67 measured in PBS (pH 7.4) + 
0.1% CrEL. a) Quantum efficiencies determined in THF. b) Quantum efficiencies determined in 
2:3 v/v EtOH:PBS. 
 
Compound ε (M-1·cm-1) λabs (nm) Φ 
26 3.9 × 104 755 5.0% a 
66 1.9 × 104 675 2.8% a 
64 3.7 × 104 767 1.2% b 
67 3.6 × 104 697 5.4% b 
89 
 
Figure 3.22. a) pH profile of both optically collected data and PA signal methods for compound 
26. b) Sample PA image of 64 in the tissue phantom using 767 nm excitation. At pH 3.0 64 is 
protonated with minimal absorbance at 767 nm, but at 8.2 64 is deprotanted and strongly absorbs 
at 767 m, hence the intense signal. c) Fluorescence imaging of 10 µM 64 using EVOS FL 
microscope equipped with a 4× objective and a Cy5 light cube filter. Lower region of image is the 
overlap of the tissue phantom over the FEP tube containing the solution of 64.  
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Figure 4.1. a) B-O chelation reaction scheme, de-methylation leads to a B-O bond formation. b) 
Normalized absorbance (solid line) and emission (dashed line) for orthomethoxy-aza-BODIPY 
(blue) and B-O chelated aza-BODIPY (red) in CHCl3. 
 
 
a            b 
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Figure 4.2. Reaction pathway for formation of an allyl protected B-O truncated BODIPY. 
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Figure 4.3. Reaction scheme for trigger coupling of 82. a) SN2 reaction to couple of H2O2 reactive 
boronic ester moiety. b) EDC mediated coupling of Cu(II) sensitive 2-picolinic ester moiety to 82. 
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APPENDIX A 
MATERIALS AND METHODS 
 
Thin-layer chromatography (TLC) was performed on glass-backed TLC plates pre-coated with 
silica gel containing an UV254 fluorescent indicator (Macherey-Nagel). Compounds were 
visualized with a 254/365nm, handheld UV lamp (UVP). Flash chromatography was performed 
using 230-400 mesh silica gel P60 (SiliCycle Inc). Preparative TLC purification was performed 
on 1.00 mm thick TLC plates pre-coated with silica gel containing an UV254 fluorescent indicator 
(Macherey-Nagel). Reversed-phased purification was performed on 20 cc Sep-Pak cartridges 
preloaded with 5g C18 sorbent (H2Os). Solvents used for anhydrous reactions were dried over 3 Å 
molecular sieves activated via heating under vacuum at 300 °C. All glassware used in anhydrous 
reactions were flame-dried or heated overnight in an oven at 160 °C and cooled immediately prior 
to use. Melting point determination was performed on a Büchi B-545 melting point apparatus. 
Copper(II) chloride was purchased from Acros. 4-Hydroxyacetophenone, 4-hydroxyacetophenone, 
4-hydroxybenzaldehyde, 2-picolinic acid, and 4-bromomethylphenylboronic acid pinacol ester 
were purchased from AK Scientific. Magnesium(II) chloride hexahydrate was purchased from 
Amresco. Kolliphor EL was purchased from Fluka. Nirtomethane was purchased from Macron. 
Cobalt(II) chloride hexahydrate was purchased from Mallinckrodt. Acetic acid, acetyl chloride, 
ammonium acetate, calcium chloride, cesium carbonate, citric acid, 2-fluorophenol 2,6-
dichlorophenol, 2,6-dibromophenol, N,N-diisopropylethylamine, 4-dimethylaminopyridine, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide, imidazole, potassium carbonate, manganese(II) 
chloride hexahydrate, potassium hydroxide, sulfur trioxide trimethylamine complex, tert-
butyldimethylsilyl chloride, tetrakis(triphenylphosphine)palladium(0), N-bromosuccinimide, and 
94 
 
trimethylamine, and triflic acid were purchased from Oakwood Products. Allyl bromide, 
bromobenzene, 4-bromophenol, 4-bromo-3-fluorophenol, benzaldehyde, boron trifluoride diethyl 
etherate, 1,3-dimethylbarbituric acid, iron(II) chloride tetrahydrate, nickel(II) chloride 
hexahydrate, sodium bicarbonate, sodium phosphate dibasic, tetrabutylammonium fluoride 
solution, tetrakis(acetonitrile)copper(I) hexafluorophosphate, tosyl chloride, crotonaldehyde, 2-
hydroxy-4-methoxyacetophenone, 3-methoxyphenol, and zinc chloride were purchased from 
Sigma-Aldrich. Triethylene glycol was purchased from TCI America. Deuterated solvents were 
purchased from Cambridge Isotope Laboratories. Agarose LE was purchased from Gold 
Biotechnology. Fluorinated ethylene propylene (FEP) tubing with a wall thickness of 0.01” and 
inner diameters measuring 0.06” or 0.08” were purchased from McMaster-Carr.  
All buffers used for pH titrations were prepared by mixing 0.1 M citric acid in deionized H2O and 
0.2 M dibasic sodium phosphate in deionized H2O at different ratios. The solutions were diluted 
by ½ with deionized H2O. Fine adjustments to the pH were made by addition of aqueous 0.1 M HCl 
or 0.1 M NaOH. The pH values were determined using a Mettler Toledo SevenCompact pH meter 
calibrated using 4.0, 7.0 10.0 standard buffers at 25°C. The pH range of the buffers was 3.0 to 8.2. 
Kolliphor EL was added to each buffer to make a 0.1% by weight solution. 
Tissue phantoms were prepared by dissolving agarose (4.0 g) in a solution of 2% milk (8.0 mL) 
and deionized H2O (72.0 mL). The suspension was heated in a microwave oven for 1 min to afford 
a viscous gel which was poured into a mold made from a 50 mL centrifuge tube. The gel was 
cooled in a refrigerator for a minimum of 5 hrs. Immediately prior to use, the phantom was 
removed from the mold and cut with a razor such that there was 1.0 cm of gel above and below 
where the FEP tubes were inserted. 
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APPENDIX B 
SYNTHESIS PROTOCOL 
 
(E)-chalcone (14). A solution of benzaldehyde (5.0 g, 47 mmol) and acetophenone (5.6 mL, 47 
mmol) was suspended in methanol (40 mL) and 20% KOH solution (40 mL, 141 mmol) then 
stirred at room temperature over 12 hours. Yellow precipitate crashed out and was filtered off and 
rinsed with DI H2O 2 × 50 mL then hexanes 2 × 50 mL. Resultant yellow solid was finely crushed 
and dried under vacuum to yield the final product as a yellow solid (6.71 g, 32 mmol, 68%). 1H 
NMR (400 MHz, CDCl3)
 δ 8.03 (d, J = 7.1 Hz, 2H), 7.82 (d, J = 15.7 Hz, 1H), 7.64 – 7.62 (m, 
2H), 7.57 – 7.47 (m, 4H), 7.41-7.39 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 190.67, 145.05, 
138.41, 135.09, 133.08, 130.83, 129.22, 128.90, 128.78, 128.74, 122.25.  
4-nitro-1,3-diphenylbutan-1-one (15). 14 (4.19 g, 20.1 mmol) was suspended in a solution of 
nitromethane (21.6 mL, 400 mmol), 20% KOH solution (8.5 mL, 30.2 mmol), and ethanol (30 
mL). The reaction was refluxed at 75°C for 2 hours then solvent was removed under reduced 
pressure. The crude residue was purified using silica gel flash chromatography (1:9 v/v 
EtOAc:hexanes). The product was subsequently recrystallized using 1:9 v/v ethyl acetate: hexanes 
to isolate a white solid (3.35 g, 12.4 mmol, 62%). 1H NMR (400 MHz, CDCl3)
  δ 7.92 (d, J = 7.3 
Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 7.36 – 7.27 (m, 4H), 4.84 (dd, J = 12.5, 
6.6 Hz, 1H), 4.69 (dd, J = 12.4, 8.0 Hz, 1H), 4.23 (p, J = 7.1 Hz, 1H), 3.46 (t, J = 6.9 Hz, 2H).  
1-(3-fluoro-4-hydroxyphenyl)ethan-1-one (16). 2-fluorphenol (11.21g, 100 mmol) was 
dissolved into 100 mL of CH2Cl2 and cooled to 0°C. Triethyl amine (25.3g, 250 mmol) was added 
followed by slow addition of acetyl chloride (9.42g, 120 mmol). Upon addition, reaction was 
brought to room temperature and stirred overnight. Solution was quenched with addition of brine 
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and extracted with CH2Cl2 4 x 75 mL. Organic phases was dried over Na2SO4 and concentrated 
under vacuum, crude residue was filtered through a silica plug with 1:9 EtOAc:hexanes to yield 
the crude intermediate, 2-fluoro acetate as a colorless oil. 2-fluoro acetate was cooled to 0°C and 
trifluoromethane sulfonic acid (10 mL) was slowly added. Upon addition of acid, the solution was 
brought to room temperature and heated at 50 °C overnight. Solution was cooled to 0°C and slowly 
quenched using a sodium bicarbonate solution. Aqueous layer was extracted with 3 × 50 mL 
EtOAc and purified using silica gel chromatography with 1:3 EtOAc to hexanes to yield a white 
solid (3.32g, 21.5 mmol, 22% yield across two steps). 1H NMR (500 MHz, CD3OD) δ 7.67 (t, J = 
9.2 Hz, 3H), 6.96 (t, J = 8.6 Hz, 1H), 2.51 (s, 3H). 13C NMR (125 MHz, CD3OD) δ 197.22, 152.28, 
150.35, 129.42, 126.18, 117.14, 115.88, 115.73, 25.12. 19F NMR (470 MHz, CD3OD) δ -139.08. 
 (E)-1-(3-fluoro-4-hydroxyphenyl)-3-phenylprop-2-en-1-one (17). 16 (3.32 g, 21.5 mmol) was 
dissolved into 20 mL of methanol and charged with benzaldehyde (2.74 g, 25.9 mmol) and 20% 
KOH solution (18 mL, 65 mmol). Solution was stirred at room temperature for 12 hours as product 
crashed out of solution. Reaction was filtered and washed with DI H2O and hexanes to yield pure 
product as a yellow solid (4.46 g, 18.4 mmol, 86%). 1H NMR (500 MHz, CD3OD) δ 7.87 (m, J = 
9.2 Hz, 3H), 6.96 (t, J = 8.6 Hz, 1H). 19F NMR (470 MHz, CD3OD) δ -138.78 (t, J = 10.2 Hz). 
1-(3-fluoro-4-hydroxyphenyl)-4-nitro-3-phenylbutan-1-one (18). 17 (1.0 g, 4.13 mmol) was 
dissolved into 15 mL of ethanol and charged with nitromethane (4.4 mL, 82.6 mmol) and 20% 
KOH solution (0.28 mL, 4.9 mmol). Solution was refluxed at 70°C for 12 hours then cooled to 
room temperature and solvent reduced in vacuo. Crude residue was purified using silica gel 
chromatography using 1:3 ethyl acetate to hexanes to yield a yellow oil (0.92 g, 3.04 mmol, 77%). 
1H NMR (400 MHz, CDCl3) δ 7.84 – 7.80 (m, 1H), 7.69 – 7.63 (m, 2H), 7.51 – 7.41 (m, 1H), 7.35 
– 7.27 (m, 3H), 7.10 – 6.02 (m, 1H), 4.81 (dd, J = 12.5, 6.7 Hz, 1H), 4.68 (dd, J = 12.5, 7.8 Hz, 
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1H), 4.20 (t, J = 7.1 Hz, 1H), 3.38 (dd, J = 7.0, 5.7 Hz, 2H). 19F NMR (375 MHz, CDCl3) δ -139.73 
(t, J = 9.6 Hz). 
(Z)-4-(5-((3,5-diphenyl-2H-pyrrol-2-ylidene)amino)-4-phenyl-1H-pyrrol-2-yl)-2-
fluorophenol (19). 18 and 15 were dissolved into 15 mL of 1-butanol and charged with ammonium 
acetate (1.68 g, 21.8 mmol). Solution was refluxed at 115 °C for 5 hours then solvent was removed 
in vacuo. Crude solvent was washed with DI H2O 3 × 50 mL then 2 × 50 mL brine. Reaction was 
purified with silica gel chromatography using 7:13 EtOAc to hexanes to isolate a dark blue solid 
(95.8 mg, 0.2 mmol, 32%). 
4-(5,5-difluoro-1,7,9-triphenyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-
yl)-2-fluorophenol (20). 19 was suspended in 25 mL anhydrous CH2Cl2 and anhydrous 
diisopropylethylamine (0.4 mL, 3 mmol). Boron trifluoride diethyl etherate ( 0.3 mL, 2 mmol) was 
added dropwise and the stirred at room temperature for 15 hours then extracted with brine and 4 × 
10 mL of CH2Cl2. Product was purified with silica gel chromatography and 1:9 EtOAc to hexanes 
to isolate a dark green film (48.04 mg, 0.09 mmol, 46%). 
2,6-Dichlorophenyl acetate (21). A solution of 2,6-dichlorophenol (9.1 g, 55.8 mmol) and 
triethylamine (19.4 mL, 139.0 mmol) in CH2Cl2 (100 mL) was cooled to 0°C in an ice-bath. After 
acetyl chloride (4.8 mL, 67.0 mmol) was added dropwise, the solution was warmed to room 
temperature and stirred for 2.5 hours. The reaction was treated with sat. Na2CO3 (75 mL) and 
extracted with CH2Cl2 (3 × 25 mL). The combined organic fractions were dried (Na2SO4), filtered 
and concentrated to afford the crude residue which was purified via flash chromatography on a 
silica column (1:9 v/v EtOAc:hexanes) to afford the title compound as a colorless oil (10.7 g, 52.5 
mmol, 94.1%). 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 8.1, 1.4 Hz), 7.13 (ddd, J = 10.5, 7.3, 
1.9 Hz, 1H), 2.39 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 167.5, 144.3, 129.2, 128.9, 127.4, 20.5. 
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3,5-Dichloro-4-hydroxyacetophenone (22).  A solution of 21 (10.7 g, 52.2 mmol) and 
trifluoromethanesulfonic acid (20 mL) was stirred at 40°C for 16 hours. The reaction was cooled 
to 0°C in an ice-bath, treated with sat. Na2CO3 until the reaction became neutral, and extracted 
with EtOAc (4 × 75 mL). The combined organic fractions were dried (Na2SO4), filtered and 
concentrated to afford the crude residue which was purified via flash chromatography on a silica 
column (1:3 v/v EtOAc:hexanes) to afford the title compound as a white solid (7.5 g, 36.6 mmol, 
70.1%). 1H NMR (500 MHz, DMSO-d6) δ 7.91 (s, 2H), 2.52 (s, 3H). 13C NMR (125 MHz, DMSO-
d6) δ 195.5, 154, 130.3, 129.5, 122.8, 27.1. m.p. = 162.5°C. HR-MS calculated for C8H6Cl2O2 [M-
H]+ m/z 204.9823, found 204.9819. 
3',5'-Dichloro-4'-hydroxychalcone (23). A solution of 22 (6.35 g, 31.0 mmol), benzaldehyde (3.8 
mL, 37.2 mmol) in MeOH (75 mL) was treated with KOH (20% w/w in H2O, 17.4 mL) and stirred 
at room temperature for 24 hours. MeOH was removed under reduced pressure and the remaining 
aqueous solution was acidified with AcOH. The reaction was extracted with EtOAc (4 × 25 mL). 
The combined organic fractions were dried (Na2SO4), filtered and concentrated to afford the crude 
residue which was purified via flash chromatography on a silica column (3:17 v/v EtOAc:hexanes) 
to afford the title compound as an off-white solid (8.63 g, 29.4 mmol, 95.0%). 1H NMR (500 MHz, 
Acetone-d6) δ 8.17 (s, 2H), 7.93 (d, J = 15.6 Hz, 1H), 7.88–7.83 (m, 2H), 7.81 (d, J = 15.6 Hz, 
1H), 7.49–7.43 (m, 3H). 13C NMR (125 MHz, Acetone-d6) δ 205.6, 185.7, 153.2, 144.8, 135.2, 
131.4, 130.8, 129.3, 129.1, 129.1, 129.1, 122.3, 121.2. m.p. = 163°C. HR-MS calculated for 
C15H10Cl2O2 [M-H]
+ m/z 293.0136, found 293.0142. 
1-(3,5-Dichloro-4-hydroxyphenyl)-4-nitro-3-phenylbutan-1-one (24). A solution of 23 (8.6 g, 
29.4 mmol, 1.0 equiv) in EtOH (50 mL) was treated with MeNO2 (16.0 mL, 298.8 mmol) and 
KOH (20% w/w in H2O, 10.0 mL). The reaction was refluxed for 12 hrs. EtOH was removed with 
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reduced pressure and the resultant aqueous solution was diluted with brine (100 mL) and extracted 
with EtOAc (4 × 25 mL). The combined organic fractions were dried (Na2SO4), filtered and 
concentrated to afford the crude residue which was purified via flash chromatography on a silica 
column (3:17 v/v EtOAc:hexanes) to afford the title compound as a tan oil (5.1 g, 14.2 mmol, 
50.5%). 1H NMR (500 MHz, CDCl3) δ 7.84 (s, 2H), 7.36–7.28 (m, 5H), 4.82 (dd, J = 12.6, 6.8Hz, 
1 H), 4.70 (dd, J = 12.5, 7.8 Hz, 1H) 4.21 (p, J = 7.1 Hz, 1H), 3.44-3.34 (m, 2H). 13C NMR (125 
MHz, CDCl3) δ 193.9, 152.5, 139.0, 130.1, 129.4, 128.8, 128.3, 127.7, 121.9, 79.7, 41.4, 39.5. 
HR-MS calculated for C16H13Cl2NO4 [M-H]
+ m/z 354.0300, found 354.0302. 
(Z)-2,6-dichloro-4-(5-((3,5-diphenyl-2H-pyrrol-2-ylidene)amino)-4-phenyl-1H-pyrrol-2-
yl)phenol (25). A solution of 24 (600 mg, 1.7 mmol) and chalcone (1.4 g, 5.1 mmol) was dissolved 
in n-butanol (15 mL). Ammonium acetate (2.0 g, 25.4 mmol) was added and the reaction was 
stirred at 115°C for 3 hours. Volatiles were removed under reduced pressure. The crude residue 
suspended in brine (100 mL) and extracted with EtOAc (3 × 15 mL). The combined organic 
fractions were dried (Na2SO4), filtered and concentrated to afford the crude residue which was 
purified via flash chromatography on a silica column (3:7 v/v CH2Cl2:hexanes to 100% CH2Cl2) 
to afford the title compound as a dark blue film (320 mg, 0.6 mmol, 35.3%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.18 (s, 2H), 8.06–8.05 (m, 4H), 7.96 (d, J = 7.7 Hz, 1H), 7.54 (t, J = 7.6 Hz, 1H), 
7.50-7.33 (m, 6H). 13C NMR (125 MHz, DMSO-d6) δ 133.4, 130.2, 129.0, 128.9, 128.9, 128.8, 
128.8, 128.6, 128.5, 128.4, 128.2, 128.0, 127.8, 127.8, 127.7, 126.7, 125.1, 110.0. 
3,5-Dichloro-4-hydroxy-aza-BODIPY (26). A solution of 25 (128 mg, 0.24 mmol) in anhydrous 
CH2Cl2 (15 mL) was treated with anhydrous DIPEA (0.6 mL, 2.4 mmol) and boron trifluoride 
etherate (0.45 mL, 3.6 mmol). The solution was stirred at room temperature for 3 hours and 
concentrated under reduced pressure. The crude residue was purified via flash chromatography on 
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a silica column (1:1 v/v CH2Cl2:hexanes) to afford the title compound as a dark green film (118.6 
mg, 0.2 mmol, 85.1%). 1H NMR (500 MHz, DMSO-d6) δ 8.19 (s, 2H), 8.13–8.07 (m, 6H), 7.68 
(s, 1H), 7.55–7.42 (m, 10H). 13C NMR (125 MHz, acetone-d6) δ 158.8, 156.6, 153.2, 145.8, 145.3, 
143.8, 143.3, 132.4, 132.2, 131.8, 131.7, 130.8, 130.5, 130.4, 130.2, 129.9, 129.9, 129.4, 123.3, 
123.2, 121.1, 120.7. HR-MS calculated for C32H20BCl2F2N3O [M-H]
+ m/z 582.1123, found 
582.1129. 
2,6-Dibromophenyl acetate (27). A solution of 2,6-dibromophenol (3.0 g, 11.9 mmol) and 
triethylamine (3.32 mL, 23.8 mmol) in CH2Cl2 (100 mL) was cooled to 0°C in an ice-bath. After 
acetyl chloride (1.02 mL, 14.3 mmol) was added dropwise, the solution was warmed to room 
temperature and stirred for 30 mins. The reaction was treated with sat. Na2CO3 (75 mL) and 
extracted with CH2Cl2 (3 × 20 mL). The combined organic fractions were dried (Na2SO4), filtered 
and concentrated to afford the crude residue which was purified via flash chromatography on a 
silica column (1:40 v/v EtOAc to hexanes) to afford the title compound as a colorless oil (3.39 g, 
11.5 mmol, 97%). 
3,5-Dibromo-4-hydroxyacetophenone (28).  A solution of 27 (3.39 g, 11.5 mmol) and 
trifluoromethanesulfonic acid (10 mL) was stirred at room temperature for 18 hours. The reaction 
was cooled to 0°C in an ice-bath, treated with sat. Na2CO3 until the reaction became neutral, and 
extracted with EtOAc (3 × 20 mL). The combined organic fractions were dried (Na2SO4), filtered 
and concentrated to afford the crude residue which was purified via flash chromatography on a 
silica column (1:3 v/v EtOAc:hexanes) to afford the title compound as a white solid (2.61 g, 8.86 
mmol, 77%). 1H NMR (500 MHz, acetone-d6) δ 8.13 (s, 2H), 2.57(s, 3H). 13C NMR (125 MHz, 
acetone-d6) δ 210.77, 199.19, 160.03, 138.12, 137.13, 115.92, 30.97. 
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3',5'-Dibromo-4'-hydroxychalcone (29). A solution of 28 (1.08 g, 3.7 mmol), benzaldehyde 
(0.94 mL, 9.2 mmol) in MeOH (10 mL) was treated with boron trifluoride etherate (0.23 mL, 1.8 
mmol) and stirred at 70° for 24 hours. Reaction was filtered and washed with H2O (50mL) and 
hexanes (50 mL) to afford the title compound a yellow solid (1.15 g, 3.0 mmol, 82%).  
1-(3,5-Dibromo-4-hydroxyphenyl)-4-nitro-3-phenylbutan-1-one (30). A solution of 29 (0.769 
g, 2.0 mmol) in EtOH (15 mL) was treated with MeNO2 (1.6 mL, 30 mmol) and KOH (0.14 g, 2.4 
mmol). The reaction was refluxed for 18 hrs. EtOH was removed with reduced pressure and the 
resultant residue was purified via flash chromatography on a silica column (1:4 v/v EtOAc:hexanes) 
to afford the title compound as a tan oil (0.27 g, 0.6 mmol, 30%). 1H NMR (400 MHz, CDCl3) δ 
8.00 (s, 2H), 7.35 – 7.23 (m, 5H), 4.79 (dd, J = 12.5, 6.8 Hz, 1H), 4.67 (dd, J = 12.5, 7.8 Hz, 1H), 
4.22 – 4.04 (m, 1H), 3.36 (t, J = 6.2 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 193.63, 154.02, 
138.98, 132.58, 131.22, 129.35, 128.24, 127.66, 110.51, 79.64, 41.43, 39.42. 
(Z)-2,6-dibromo-4-(5-((3,5-diphenyl-2H-pyrrol-2-ylidene)amino)-4-phenyl-1H-pyrrol-2-
yl)phenol (31). A solution of 30 (0.27 mg, 0.6 mmol) and chalcone (0.49 g, 1.8 mmol) was 
dissolved in n-butanol (15 mL). Ammonium acetate (0.7 g, 9.1 mmol) was added and the reaction 
was stirred at 115°C for 3 hours. Volatiles were removed under reduced pressure. The crude 
residue suspended in brine (100 mL) and extracted with EtOAc (3 × 15 mL). The combined organic 
fractions were dried (Na2SO4), filtered and concentrated to afford the crude residue which was 
purified via flash chromatography on a silica column (3:7 v/v CH2Cl2:hexanes to 100% CH2Cl2) 
to afford the title compound as a dark blue film (67 mg, 0.11 mmol, 18%). 1H NMR (500 MHz, 
DMSO-d6) δ 8.33 (s, 2H), 8.04 (d, J = 7.0 Hz, 2H), 7.99 (s, 2H), 7.91 (d, J = 7.6 Hz, 2H), 7.52 (t, 
J = 7.6 Hz, 2H), 7.46 – 7.29 (m, 8H). 
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3,5-Dibromo-4-hydroxy-aza-BODIPY (32). A solution of 31 (67 mg, 0.11 mmol) in anhydrous 
CH2Cl2 (10 mL) was treated with anhydrous DIPEA (0.3 mL, 1.3 mmol) and boron trifluoride 
etherate (0.135 mL, 1.1 mmol). The solution was stirred at room temperature for 3 hours and 
concentrated under reduced pressure. The crude residue was purified via flash chromatography on 
a silica column (1:1 v/v CH2Cl2:hexanes) to afford the title compound as a dark green film (70.4 
mg, 0.105 mmol, 97%). HR-MS calculated for C32H20BBr2F2N3O [M-H]
+ m/z 672.0092, found 
672.0087. 
4-(2-(3-hydroxypropoxy)ethoxy) acetophenone (33). 4-hydroxyacetophenone (2.5 g, 14.7 mmol) 
was dissolved into 40 mL of DMF and charged with 2-(2-chloroethoxy)ethanol (2.3 mL, 22 mmol) 
and K2CO3 (5.1 g, 37 mmol). Solution was refluxed at 160°C for 18 hours then cooled to room 
temperature and solvent reduced in vacuo then extracted with brine and 4 × 25 mL EtOAc. Purified 
using silica gel chromatography using CH2Cl2 to yield a colorless oil (3.3 g, 14.7 mmol, 100%). 
1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 4.21 – 4.19 (m, 
2H), 3.90 – 3.88 (m, 2H), 3.77 (bs, 2H), 3.69 – 3.67 (m, 2H), 2.55 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ 197.08, 162.80, 130.83, 130.75, 114.46, 72.90, 69.65, 67.78, 61.96, 26.60. 
 (E)-1-(4-(2-(2-hydroxyethoxy)ethyl)phenyl)-3-phenylprop-2-en-1-one (34). 33 (3.3 g, 14.7 
mmol) and benzaldehyde (1.8 mL, 17.7 mmol) was suspended in 40 mL of methanol and 20% 
KOH solution (8.3 mL, 29.4 mmol). Solution was heated at 40 °C over 4 days. Methanol was 
removed under reduced pressure and extracted with brine and EtOAc 3 × 25 mL. The organic 
phase was dried over Na2SO3 and concentrate under reduced pressure then purified with silica gel 
chromatography with 3:2 EtOAc to hexanes to yield a yellow oil that solidified while standing 
(3.46 g, 11.1 mmol, 75%). 1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.8 Hz, 2H), 7.82 (d, J = 
15.7 Hz, 1H), 7.56 (d, J = 15.7 Hz, 2H), 7.43-7.42 (m, 3H), 7.01 (d, J = 8.8 Hz, 2H), 4.23 (dd, J = 
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5.3, 4.0 Hz, 2H), 3.93 – 3.89 (m, 2H), 3.79 (dd, J = 5.4, 3.7 Hz, 2H), 3.70 (dd, J = 5.3, 3.9 Hz, 
2H). 13C NMR (125 MHz, CDCl3) δ 188.93, 162.78, 144.30, 135.29, 131.56, 131.07, 130.61, 
129.17, 128.62, 122.07, 114.65, 72.93, 69.69, 67.84, 62.00, 60.65. 
1-(4-(2-(2-hydroxyethoxy)ethyl)phenyl)-4-nitro-3-phenylbutan-1-one (35). 34 (3.5 g, 11.1 
mmol) was suspended in ethanol (50 mL), nitromethane (8.9 mL, 116 mmol), and 20% KOH 
solution (3.7 mL, 13.3 mmol). Mixture was refluxed at 70°C for 2.5 hours then reduced under 
vacuum and purified with silica gel flash chromatography using 3:2 EtOAc to hexanes to yield an 
orange oil (3.7 g, 9.9 mmol, 90%). 1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 8.9 Hz, 2H), 7.37 – 
7.24 (m, 5H), 6.95 (d, J = 8.9 Hz, 2H), 4.84 (dd, J = 12.5, 6.4 Hz, 1H), 4.69 (dd, J = 12.5, 8.2 Hz, 
1H), 4.20 (dd, J = 5.4, 3.9 Hz, 3H), 3.90-3.88 (m, 2H), 3.69-3.67 (m, 2H), 3.42 (dd, J= 17.5, 6.3, 
1H), 3.37 (dd, J= 17.5, 7.7, 1H). 13C NMR (125 MHz, CDCl3) δ 195.61, 163.15, 139.50, 130.60, 
129.89, 129.28, 128.06, 127.69, 114.64, 79.86, 72.89, 69.62, 67.82, 61.97, 41.42, 39.63. 
(Z)-2,6-dichloro-4-(5-((5-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-3-phenyl-2H-pyrrol-2-
ylidene)amino)-4-phenyl-1H-pyrrol-2-yl)phenol (36). A solution of 35 (310 mg, 3.7 mmol) and 
26 (320 mg, 3.7 mmol) was dissolved in n-butanol (15 mL). Ammonium acetate (1.35 g, 87 mmol) 
was added and the reaction was stirred at 115°C for 2 hours. Volatiles were removed under reduced 
pressure and the crude residue was then purified via flash chromatography on a silica column (1:1 
v/v CH2Cl2: EtOAc) to afford the title compound as a dark blue film (210 mg, 0.3 mmol, 38%). 
2,6-dichloro-4-(5,5-difluoro-7-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)-1,9-diphenyl-5H-
5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-yl)phenol) (37). A solution of 36 (50.9 
mg, 0.08 mmol) in anhydrous CH2Cl2 (10 mL) was treated with anhydrous diisopropylethylamine 
(0.14 mL, 0.8 mmol) and boron trifluoride etherate (0.15 mL, 1.2 mmol). The solution was stirred 
at room temperature for 3 hours and concentrated under reduced pressure. The crude residue was 
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purified via flash chromatography on a silica column (1:1 v/v CH2Cl2:EtOAc) to afford the title 
compound as a dark green film (19.7 mg, 0.03 mmol, 36%). 
1-(2,4-bis(2-(2-hydroxyethoxy)ethoxy)phenyl)ethan-1-one (38). 2,4-dihydroxyacetophenone 
(2.0 g, 13.1 mmol) was dissolved into 40 mL of DMF and charged with 2-(2-chloroethoxy)ethanol 
(3.5 mL, 33 mmol) and K2CO3 (6.36 g, 46 mmol). Solution was refluxed at 160°C for 12 hours 
then cooled to room temperature and solvent reduced in vacuo then extracted with brine and 5 × 
25 mL EtOAc. Purified using silica gel chromatography using 3:47 methanol:CH2Cl2 to yield a 
yellow oil (4.0 g, 12.2 mmol, 93%). 1H NMR (500 MHz, CDCl3) δ 7.80 (d, J = 8.9 Hz, 1H), 6.53-
6.511 (m, 2H), 4.20 – 4.16 (m, 4H), 3.90 – 3.85 (m, 4H), 3.78 – 3.74 (m, 4H), 3.67-3.64 (m, 4H), 
2.59 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 198.02, 163.71, 160.40, 132.91, 121.74, 106.10, 
100.24, 72.91, 72.76, 69.67, 69.66, 68.06, 67.84, 62.01, 61.93, 32.10. 
 (E)-1-(2,4-bis(2-(2-hydroxyethoxy)ethoxy)phenyl)-3-phenylprop-2-en-1-one (39). 38 (4.0 g, 
12.2 mmol) and benzaldehyde (1.49 mL, 14.6 mmol) was suspended in methanol (30 mL) and 
20% KOH solution (6.8 mL, 24.4 mmol). Solution was stirred at room temperature for 24 hours. 
Reaction was concentrated under vacuum and resuspended in brine and extracted with 4 × 25 mL 
EtOAc. Organic phase was dried over Na2SO4 and concentrated, the crude residue was purified 
with silica gel flash chromatography with 3:47 methanol:CH2Cl2 to yield a yellow oil (2.97 g, 7.1 
mmol, 58%). 1H NMR (500 MHz, CDCl3) δ 7.71 (dd, J = 8.6, 1.0 Hz, 1H), 7.61 (d, J = 2.6 Hz, 
2H), 7.56 (dd, J = 7.6, 2.0 Hz, 2H), 7.35-7.30 (m, 2H), 6.50 – 6.47 (m, 2H), 4.13-4.09 (m, 4H), 
3.79 – 3.77 (m, 4H), 3.71 – 3.69 (m, 2H), 3.60 – 3.59 (m, 4H), 3.51 – 3.49 (m, 2H). 13C NMR (125 
MHz, CDCl3) δ 190.50, 163.56, 159.89, 142.17, 135.61, 133.21, 130.28, 129.07, 128.53, 127.51, 
122.45, 106.46, 100.38, 72.97, 72.84, 69.62, 69.58, 68.36, 67.85, 61.80, 61.77. 
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1-(2,4-bis(2-(2-hydroxyethoxy)ethoxy)phenyl)-4-nitro-3-phenylbutan-1-one (40). 39 (3.0 g, 
7.1 mmol) was suspended in ethanol (35 mL), nitromethane (6.7 mL, 107 mmol), and 20% KOH 
solution (2.4 mL, 8.6 mmol). Mixture was refluxed at 70°C for 2  hours then reduced under vacuum 
and purified with silica gel flash chromatography using 3:47 methanol: CH2Cl2 to yield an orange 
oil (2.8 g, 5.9 mmol, 82%). 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 8.6 Hz, 1H), 7.28 – 7.23 
(m, 4H), 7.20 (t, J = 6.7 Hz, 1H), 6.48 – 6.45 (m, 2H), 4.79 (dd, J = 12.4, 6.2 Hz, 1H), 4.61 (dd, J 
= 12.4, 8.6 Hz, 1H), 4.16 – 4.10 (m, 5H), 3.79 (dt, J = 9.1, 4.9 Hz, 4H), 3.71 (bs, 2H), 3.62 – 3.60 
(m, 4H), 3.50 – 3.45 (m, 4H). 13C NMR (125 MHz, CDCl3) δ 196.89, 164.08, 160.33, 140.22, 
133.04, 129.04, 127.78, 127.71, 120.68, 106.46, 99.95, 80.24, 72.92, 72.71, 69.55, 69.49, 68.06, 
67.88, 61.82, 46.93, 39.90. 
2,2'-((((4-(7-(3,5-dichloro-4-hydroxyphenyl)-diphenyl-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triaza)-1,3-phenylene)bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethan-1-ol) (41). A 
solution of 40 (250 mg, 0.71 mmol) and 26 (370 mg, 0.78 mmol) was dissolved in n-butanol (10 
mL). Ammonium acetate (1.1 g, 14 mmol) was added and the reaction was stirred at 115°C for 2 
hours. Volatiles were removed under reduced pressure and the crude residue was then purified via 
flash chromatography on a silica column (100% CH2Cl2) to afford the title compound as a dark 
blue film (43.3 mg, 0.06 mmol, 8.3% yield). 
2,2'-((((4-(7-(3,5-dichloro-4-hydroxyphenyl)-5,5-difluoro-1,9-diphenyl-5H-4l4,5l4-
dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinin-3-yl)-1,3-phenylene)bis(oxy))bis(ethane-2,1-
diyl))bis(oxy))bis(ethan-1-ol) (42). A solution of 41 (43.3 mg, 0.06 mmol) in anhydrous CH2Cl2 
(20 mL) was treated with anhydrous diisopropylethylamine (0.14 mL, 0.8 mmol) and boron 
trifluoride etherate (0.15 mL, 1.2 mmol). The solution was stirred at room temperature for 12 hours 
and extracted with brine then 2 × 15 mL of 1:1 v/v isopropanol:CH2Cl2. Organic phases was dried 
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over Na2SO4 then concentrated under reduced pressure. The crude residue was purified via flash 
chromatography on a silica column (1:19 v/v methanol:CH2Cl2) to afford the title compound as a 
dark green film (38.8 mg, 0.05 mmol, 84%). 
(E)-1-phenylbut-2-en-1-ol (43). Bromobenzene (3.0 g, 19.1 mmol) was suspended in 20 mL 
anhydrous THF in a 100 mL flame dried flask. The solution was cooled to -78°C in an acetone dry 
ice bath and treated dropwise with 2.5 M n-butyl Li (8.0 mL, 20.0 mmol). After 45 mins at -78°C 
the reaction was treated with crotonaldehyde (1.47 g, 21.0 mmol) and brought to room temperature 
upon addition completion. Reaction was allowed to stir at room temperature for 2.5 hours then 
quenched with 3 mL of a 10% HCl solution. The solution was diluted with brine and extracted 
with 3 × 10 mL EtOAc, organic layer was dried with Na2SO4 and concentrated in vacuo. The crude 
residue was purified using flash chromatography and 1:9 EtOAc to hexanes to isolate final product 
as a yellow oil (2.77 g, 18.7 mmol, 98%). 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.37 (m, 4H), 
7.32-7.29 (m, 1H), 5.83 – 5.71 (m, 2H), 5.18 (d, J = 6.6 Hz, 1H), 1.76 (d, J = 6.1 Hz, 3H). 13C 
NMR (125 MHz, CDCl3) δ 143.65, 133.90, 128.71, 127.74, 127.67, 126.39, 75.48, 75.41, 18.00. 
 (E)-1-phenylbut-2-en-1-one (44). 43 (2.77 g, 18.7 mmol) was suspended in 5 mL of DMSO and 
charged with 2-iodoxybenzoic acid (6.28 g, 22.4 mmol). The slurry was stirred for overnight and 
quenched with 100 mL of brine and filtered, the filtrate was washed with 3 × 25 mL CH2Cl2. The 
aqueous layer was extracted with 3 × 15 mL CH2Cl2, dried with Na2SO4 and purified with silica 
gel chromatography with 1:50 EtOAc to hexanes to yield the final product as pale yellow oil (2.19 
g, 14.9 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 2H), 7.54 – 7.48 (m, 1H), 
7.45 – 7.40 (m, 2H), 7.05 (dqd, J = 15.2, 6.8, 1.7 Hz, 1H), 6.90-6.86 (m, 1H), 1.96 (ddd, J = 6.8, 
2.6, 1.5 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 190.92, 145.29, 138.07, 132.82, 128.71, 127.69, 
18.84. 
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3-methyl-4-nitro-1-phenylbutan-1-one (45). 44 (2.19 g, 14.9 mmol) was dissolved in ethanol 
(30 mL) and nitromethane (12 mL, 225 mmol) then charged with 20% w/v KOH (4.26 mL, 18 
mmol) and refluxed at 70°C. After 7 hours the solution was cooled and dried under reduced 
pressure. The crude residue was columned using flash chromatography and 1:9 EtOAc to hexanes 
to isolate final product as a pale yellow oil (2.55 g, 12.3 mmol, 83%). 1H NMR (400 MHz, CDCl3) 
δ 7.91 (d, J = 8.4 Hz, 2H), 7.55 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.8 Hz, 2H), 4.50 (ddd, J = 11.9, 
5.9, 0.9 Hz, 1H), 4.39 (ddd, J = 12.0, 6.4, 1.2 Hz, 1H), 3.15 – 3.08 (m, 1H), 3.01 – 2.94 (m, 2H), 
1.11 (d, J = 6.6 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 197.94, 136.81, 133.68, 128.94, 128.19, 
80.74, 41.93, 28.82, 17.77. 
1-(allyloxy)-4-bromo-2-fluorobenzene (46). 4-bromo-2-fluorophenol (5.0 g, 26.2 mmol) was 
suspended in 50 mL acetone and charged with K2CO3 (4.7 g, 34.0 mmol) then treated with allyl 
bromide (2.49 mL, 28.8 mmol). The slurry was heated at 60°C for 7 hours then cooled down to 
room temperature, filtered, and rinsed with CH2Cl2 3 × 20 mL. The filtrate was concentrated and 
purified with silica gel chromatography with hexanes to yield the final product as colorless oil 
(5.95 g, 25.7 mmol, 98%). 1H NMR (400 MHz, CDCl3) δ 7.22 (dd, J = 10.5, 2.4 Hz, 1H), 7.15 
(ddd, J = 8.7, 2.3, 1.5 Hz, 1H), 6.82 (t, J = 8.7 Hz, 1H), 6.02 (ddt, J = 17.2, 10.6, 5.3 Hz, 1H), 5.41 
(dd, J = 17.3, 1.6 Hz, 1H), 5.30 (dd, J = 10.5, 1.4 Hz, 1H), 4.56 (d, J = 5.4 Hz, 2H). 13C NMR (100 
MHz, CDCl3) δ 132.63, 127.38, 127.34, 120.07, 119.86, 118.64, 116.76, 116.74, 112.56, 112.48, 
70.50. 19F NMR (375 MHz, CDCl3) δ -131.20. 
 (E)-1-(4-(allyloxy)-3-fluorophenyl)but-2-en-1-ol (47). 46 (2.76 g, 12 mmol) was suspended into 
25 mL dry THF and cooled to -78°C in an acetone dry ice bath and treated dropwise with 2.5 M 
n-butyl Li (5.0 mL, 12.6 mmol). After 30 mins at -78°C the reaction was treated with 
crotonaldehyde (1.1 g, 13.2 mmol) and brought to room temperature upon addition completion. 
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Reaction was allowed to stir at room temperature for 2 hours then quenched with 6 mL of a 10% 
HCl solution. The solution was diluted with brine and extracted with 4 × 15 mL EtOAc, organic 
layer was dried with Na2SO4 and concentrated in vacuo. The crude residue was purified using flash 
chromatography and 3:17 EtOAc to hexanes to isolate final product as a yellow oil (2.37 g, 10.7 
mmol, 89%). 1H NMR (400 MHz, CDCl3) δ 7.05 (dd, J = 12.2, 2.1 Hz, 1H), 6.97 (d, J = 8.5 Hz, 
1H), 6.88 (t, J = 8.4 Hz, 1H), 6.02 (ddt, J = 17.3, 10.6, 5.3 Hz, 1H), 5.71 – 5.63 (m, 1H), 5.59– 
5.53 (m, 1H), 5.39 (dd, J = 17.3, 1.6 Hz, 1H), 5.27 (dd, J = 10.5, 1.5 Hz, 1H), 4.99 (d, J = 4.2 Hz, 
1H), 4.55 (d, J = 5.3 Hz, 2H), 2.84 (d, J = 2.7 Hz, 1H), 1.68 (d, J = 6.3 Hz, 3H). 13C NMR (100 
MHz, CDCl3) δ 154.02, 151.58, 145.89, 145.78, 137.34, 137.29, 133.54, 133.09, 127.69, 121.99, 
118.30, 115.39, 114.49, 114.30, 74.29, 70.45, 17.85. 13C NMR (100 MHz, CDCl3) δ 154.02, 
151.58, 145.89, 137.34, 133.54, 133.09, 127.69, 121.99, 118.30, 115.39, 114.49, 114.30, 74.29, 
70.45, 17.85. 19F NMR (375 MHz, CDCl3) δ -134.06 – -134.17 (m). 
1-(4-(allyloxy)-3-fluorophenyl)-3-methyl-4-nitrobutan-1-one (48). 47 (2.37 g, 10.7 mmol) was 
dissolved into 10 mL DMSO and charged with 2-iodoxybenzoic acid (3.59 g, 12.8 mmol). The 
solution was stirred at room temperature for 10 mins then quenched with 100 mL brine. The 
reaction was filtered and the filtrate was washed with 2 × 20 mL CH2Cl2 then reduced in vacuo. 
Crude residue was taken up in 15 mL ethanol and nitromethane (8.6 mL, 160 mmol) then charged 
with 20% w/v KOH solution (3.6 mL, 12.9 mmol). The solution was refluxed at 70°C for 6 hours 
then cooled to room temperature and reduced under vacuum. The crude residue was purified with 
silica gel flash chromatography with 3:17 EtOAc:hexanes to isolate the final product as a yellow 
oil (2.14 g, 7.6 mmol, 71% yield across two steps). 1H NMR (500 MHz, CDCl3) δ 7.75 – 7.68 (m, 
2H), 7.02 (t, J = 8.4 Hz, 1H), 6.08 (ddt, J = 16.2, 10.6, 5.3 Hz, 1H), 5.48 (d, J = 17.4 Hz, 1H), 5.37 
(d, J = 10.6 Hz, 1H), 4.71 (d, J = 5.3 Hz, 2H), 4.54 (dd, J = 11.9, 5.8 Hz, 1H), 4.44 (dd, J = 12.0, 
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6.2 Hz, 1H), 3.10 (dd, J = 16.5, 6.0 Hz, 1H), 3.06 – 2.90 (m, 2H), 1.16 (d, J = 6.6 Hz, 3H). 13C 
NMR (125 MHz, CDCl3) δ 195.61, 153.43, 151.44, 132.13, 130.25, 125.48, 119.06, 115.99, 
114.13, 80.72, 70.20, 41.62, 28.94, 17.81. 
1-(3-fluoro-4-hydroxyphenyl)-3-methyl-4-nitrobutan-1-one (49). 48 (2.14 g, 7.6 mmol) was 
dissolved into 30 mL of CH2Cl2 and charged with 1,3-dimethylbarbituric acid (1.9 g, 12.2 mmol) 
and Pd(PPh3)4 (0.18 g. 0.15 mmol). The solution was stirred at room temperature overnight and 
monitored with TLC. Reaction was then concentrated under reduced pressure and purified using 
flash chromatography and 1:4 EtOAc to hexanes to yield the final product as a yellow oil (1.21 g, 
5.0 mmol, 66%). 1H NMR (500 MHz, CDCl3) δ 7.75 – 7.69 (m, 2H), 7.09 (t, J = 8.4 Hz, 1H), 4.54 
(dd, J = 11.9, 5.9 Hz, 1H), 4.45 (dd, J = 11.9, 6.2 Hz, 1H), 3.11 (dd, J = 16.6, 6.1 Hz, 1H), 3.01 – 
2.92 (m, 2H), 1.16 (d, J = 6.6 Hz, 3H). 13C NMR (125 MHz, CDCl3) δ 195.66, 151.98, 150.07, 
126.09, 117.40, 115.83, 115.68, 80.70, 41.64, 28.91, 17.83. 19F NMR (470 MHz, CDCl3) δ -
139.86. 
 (Z)-2-fluoro-4-(4-methyl-5-((3-methyl-5-phenyl-2H-pyrrol-2-ylidene)amino)-1H-pyrrol-2-
yl)phenol (50). 49 (0.15 g, 0.62 mmol) and 45 (0.129 g, 0.62 mmol) was dissolved in 5 mL of 1-
butanol and was treated with ammonium acetate (1.5 g, 20 mmol) then refluxed at 95°C for 3 hours. 
Reaction was cooled and concentrated under reduce pressure. The crude residue was purified with 
silica gel chromatography with 1:9 EtOAc to hexanes to isolate the final product as a blue film (38 
mg, 0.10 mmol, 17%). 
4-(5,5-difluoro-1,9-dimethyl-7-phenyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-3-yl)-2-fluorophenol (51). (38 mg, 0.10 mmol) was suspended into 5 mL 
of anhydrous CH2Cl2 then charged with anhydrous diisopropylethylamine (0.17 mL, 1.0 mmol) 
and then dropwise addition of boron trifluoride etherate (0.2 mL, 0.15 mmol). The reaction stirred 
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at room temperature for 3 hours then concentrated under reduced pressure. The crude residue was 
purified with silica gel flash chromatography with 1:9 EtOAc to hexanes to isolate the final product 
as a dark blue film (6.5 mg, 0.016 mmol, 16%). 
2-(2-(2-Hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (52). A solution of triethylene 
glycol (11 g, 73.3 mmol), triethylamine (2.6 mL, 19.1 mmol), DMAP (45 mg, 0.37 mmol), and 
CH2Cl2 (95 mL) was cooled to 0°C in an ice-bath and treated with tosyl chloride (3.5 g, 18.1 mmol). 
After 4.5 hours, 1 N HCl aqueous solution (100 mL) was added, the organic layer was separated 
and washed sequentially with H2O (100 mL) and brine (100 mL). The combined organic fractions 
were dried (Na2SO4), filtered, and concentrated to afford the crude residue which was purified via 
flash chromatography on a silica column (3:1 v/v EtOAc:hexanes) to afford the title compound as 
a colorless oil (2.74 g, 9.0 mmol, 49.7%). 1H NMR (500 MHz, CDCl3) δ 7.82 (d, J = 8.2 Hz, 2H), 
7.36 (d, J = 8.4 Hz, 2H), 4.20–4.18 (m, 2 H), 3.83–3.73 (m, 4H), 3.63 (s, 4H), 3.60–3.58 (m, 2H), 
2.47 (s, 3H). 13C NMR (125 MHz, CDCl3) δ 145.1, 133.2, 130.1, 128.2, 72.7, 71.0, 70.6, 69.4, 
69.0, 62.0, 21.9. 
4-(2-(2-(2-Hydroxyethoxy)ethoxy)ethoxy)benzaldehyde (53). A round-bottom flask was 
charged with 52 (24.4 g, 80.0 mmol), 4-hydroxybenzaldehyde (12.7 g, 104.0 mmol), K2CO3 (22.1 
g, 160.0 mmol) and anhydrous DMF (50.0 mL). After stirring at 80°C overnight, the reaction was 
cooled to room temperature and the volatiles were removed under reduced pressure. The resulting 
mixture was washed with brine (100 mL), H2O (100 mL) and extracted with 1:2 v/v 
isopropanol:CH2Cl2 (3 × 100 mL). The combined organic fractions were dried (Na2SO4), filtered, 
and concentrated under reduced pressure to afford the crude compound as a red oil which was 
purified via flash chromatography on a silica column (3:1 v/v EtOAc:hexanes) to afford the title 
compound as a colorless oil (13.3 g, 52.2 mmol, 65.3%). 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 
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1H), 7.80–7.76 (m, 2H), 7.00–6.96 (m, 2H), 4.21–4.15 (m, 2H), 3.89–3.81 (m, 2H), 3.74–3.63 (m, 
6H), 3.60–3.54 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 191.1, 163.9, 132.2, 130.2, 115.1, 72.7, 
71.0, 70.5, 69.6, 67.9, 61.9. 
1-(4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)phenyl)ethan-1-one (54). A round-bottom flask 
was charged with 52 (12.2 g, 40.0 mmol), 4-hydroxyacetophenone (7.08 g, 52.0 mmol), K2CO3 
(11.1 g, 80.0 mmol) and anhydrous DMF (50.0 mL). After stirring at 80°C overnight, the reaction 
cooled to room temperature and the volatiles were removed under reduced pressure. The resulting 
mixture was washed with brine (100 mL), H2O (100 mL) and extracted with 1:2 v/v 
isopropanol:CH2Cl2 (3 × 100 mL). The combined organic fractions were dried (Na2SO4), filtered, 
and concentrated under reduced pressure to afford the crude compound which was purified via 
flash chromatography on a silica column (3:1 v/v EtOAc:hexanes) to afford the title compound as 
a colorless oil (8.7 g, 32.2 mmol, 80.5%). 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 7.80–7.76 
(m, 2H), 7.00–6.96 (m, 2H), 4.21–4.15 (m, 2H), 3.89–3.81 (m, 2H), 3.74–3.63 (m, 6H), 3.60–3.54 
(m, 2H). 13C NMR (100 MHz, CDCl3) δ 191.1, 163.9, 132.2, 130.2, 115.1, 72.7, 71.0, 70.5, 69.6, 
67.9, 61.9. HR-MS calculated for C14H20NaO5 [M+Na]
+ m/z 291.1130, found 291.1221. 
(E)-1,3-Bis(4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)phenyl)prop-2-en-1-one (55). A pressure 
tube was charged with 53 (6.4 g, 25.0 mmol), 54 (6.7 g, 25.0 mmol), boron trifluoride etherate (3.7 
mL, 25.0 mmol) and MeOH (50 mL). The pressure tube was sealed and heated at 100°C for 48 
hours. The volatiles were removed under reduced pressure and the crude residue was purified via 
flash chromatography on a silica column (100% EtOAc to 7:93 v/v MeOH/CH2Cl2) to afford the 
title compound as a light yellow oil (6.4 g, 12.7 mmol, 50.6%). 1H NMR (400 MHz, CD3OD) δ 
8.06 (d, J = 8.8 Hz, 2H), 7.72 (d, J = 15.6 Hz, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.62 (d, J = 15.5 Hz, 
1H), 7.05 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.7 Hz, 2H), 4.25–4.11 (m, 5H), 3.90–3.82 (m, 5H), 
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3.73–3.67 (m, 4H), 3.67–3.60 (m, 10H), 3.57–3.50 (m, 5H). 13C NMR (100 MHz, CD3OD) δ 
189.6, 163.2, 161.3, 144.3, 131.2, 130.8, 130.4, 128.0, 119.2, 114.9, 114.4, 72.5, 70.6, 70.2, 69.5, 
67.7, 67.5, 61.0. HR-MS calculated for C27H37O9 [M+H]
+ m/z 505.2438, found 505.2450.  
1,3-Bis(4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)phenyl)-4-nitrobutan-1-one (56). A round-
bottom flask was charged with 55 (6.4 g, 12.7 mmol), MeNO2 (10.2 mL, 190.5 mmol), KOH (20% 
w/w in H2O, 7.2 mL, 25.4 mmol), and EtOH (15 mL). The reaction mixture was heated to reflux 
for 3 hours and then concentrated under reduced pressure. The crude residue was purified via flash 
chromatography on a silica column (7:93 v/v MeOH:CH2Cl2) to afford the title compound as a 
brown oil (5.3 g, 9.4 mmol, 74.3%). 1H NMR (400 MHz, CD3OD) δ 7.85 (d, J = 8.9 Hz, 2H), 7.18 
(d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.9 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 4.79 (dd, J = 12.5, 9.2 Hz, 
1H), 4.66 (dd, J = 12.5, 9.2 Hz, 1H), 4.14–4.10 (m, 2H), 4.08–4.02 (m, 1H), 4.02–3.99 (m, 2H), 
3.87–3.47 (m, 22H), 3.38 (dd, J = 17.4, 7.2 Hz, 1H), 3.32–3.24 (dd, J = 17.4, 7.2 Hz, 1H). 13C 
NMR (100 MHz, CD3OD) δ 196.7, 163.3, 158.3, 132.1, 130.4, 129.9, 128.8, 114.6, 114.3, 79.8, 
72.5, 70.6, 70.5, 70.2, 69.6, 69.4, 67.7, 67.3, 41.1, 39.3. HR-MS calculated for C28H40NO11 
[M+H]+ m/z 566.2601, found 566.2611.  
1-(4-(Allyloxy)-3,5-dichlorophenyl)ethan-1-one (57). A round-bottom flask was charged with 
21 (47.7 g, 233.0 mmol), allyl bromide (32.1 mL, 373.0 mmol), K2CO3 (64.4 g, 466.0 mmol) and 
MeCN (200 mL). The reaction was refluxed for 2 hours, cooled to room temperature, filtered 
through a plug of celite and washed with MeCN (100 mL). The filtrate was concentrated under 
reduced pressure and the crude residue was purified via flash chromatography on a silica column 
(1:19 v/v EtOAc:hexanes) to afford the title compound as a light yellow oil. (37.3 g, 182.0 mmol, 
78.1%). 1H NMR (500 MHz, CDCl3) δ 7.90 (s, 2H), 6.31–5.98 (m, 1H), 5.45 (dq, J = 17.2, 1.4 Hz, 
1H), 5.32 (dp, J = 10.3, 1.0 Hz, 1H), 4.65 (dt, J = 6.0, 1.3 Hz, 2H), 2.58 (s, 3H). 13C NMR (125 
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MHz, CDCl3) δ 195.0, 155.3, 134.2, 132.7, 130.4, 129.3, 119.7, 109.9, 74.9, 26.7. HR-MS 
calculated for C11H11Cl2O2 [M+H]
+ m/z 245.0136, found 245.0140.  
(E)-1-(4-(Allyloxy)-3,5-dichlorophenyl)-3-(4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)phenyl) 
prop-2-en-1-one (58): A pressure tube was charged with 53 (3.8 g, 15.0 mmol), 57 (4.4 g, 18.0 
mmol), boron trifluoride etherate (1.9 mL, 15.0 mmol) and MeOH (30 mL). The pressure tube was 
sealed and heated at 100 °C for 48 hours. The volatiles were removed under reduced pressure and 
the crude residue was purified via flash chromatography on a silica column (4:1 v/v 
EtOAc:hexanes to 100% EtOAc ) to afford the title compound as a light yellow solid (3.8 g, 8.0 
mmol, 53.2%). 1H NMR (400 MHz, CD3OD) δ 8.04 (s, 2H), 7.74 (d, J = 15.4 Hz, 1H), 7.68 (d, J 
= 8.8 Hz, 2H), 7.53 (d, J = 15.5 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.12 (ddt, J = 17.3, 10.4, 5.9 
Hz, 1H), 5.40 (dd, J = 17.2, 1.6 Hz, 1H), 5.26 (dd, J = 10.4, 1.4 Hz, 1H), 4.61 (dt, J = 5.9, 1.3 Hz, 
2H), 4.27–4.05 (m, 2H), 3.94–3.77 (m, 2H), 3.76–3.48 (m, 8H). 13C NMR (100 MHz, CD3OD) δ 
187.1, 161.6, 154.7, 146.0, 135.5, 132.9, 130.8, 130.0, 129.1, 127.6, 118.1, 114.9, 74.5, 72.5, 70.6, 
70.2, 69.5, 67.5, 61.0. m.p. = 70°C. HR-MS calculated for C24H27O6Cl2 [M+H]
+ m/z 481.1185, 
found 481.1194.  
1-(4-(Allyloxy)-3,5-dichlorophenyl)-3-(4-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)phenyl)-4-
nitrobutan-1-one (59). A round-bottom flask was charged with 58 (3.84 g, 8.0 mmol), 
nitromethane (6.4 mL, 120.0 mmol), KOH (20% w/w in H2O, 4.5 mL, 16.0 mmol), and EtOH (10 
mL). The reaction mixture was refluxed for 3 hours, cooled to room temperature, and concentrated 
under reduced pressure. The crude residue was purified via flash chromatography on a silica 
column (4:1 v/v EtOAc:hexanes) to afford the title compound as a brown oil (2.7 g, 5.0 mmol, 
61.5%). 1H NMR (400 MHz, CD3OD) δ 7.85 (s, 1H), 7.19 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.7 Hz, 
1H), 6.08 (ddt, J = 17.3, 10.4, 6.0 Hz, 1H), 5.37 (dq, J = 17.2, 1.5 Hz, 1H), 5.23 (dq, J = 10.5, 1.3 
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Hz, 1H), 4.81 (dd, J = 12.7, 6.1 Hz, 1H), 4.66 (dd, J = 12.6, 9.2 Hz, 1H), 4.56 (dt, J = 6.0, 1.3 Hz, 
2H), 4.08–3.93 (m, 3H), 3.83–3.73 (m, 2H), 3.71–3.48 (m, 9H), 3.42 (dd, J = 17.8, 7.1 Hz, 1H), 
3.34 (dd, J = 17.8, 6.8 Hz, 1H). 13C NMR (100 MHz, CD3OD) δ 195.0, 158.4, 155.0, 133.9, 132.8, 
131.8, 129.9, 128.8, 128.8, 118.2, 114.6, 79.6, 74.5, 72.5, 70.5, 70.2, 69.6, 67.3, 61.0, 41.4, 39.0. 
HR-MS calculated for C27H28NO8Cl2 [M+H]
+ m/z 564.1192, found 564.1187.  
(Z)-2,2'-(((((((2-((5-(4-(Allyloxy)-3,5-dichlorophenyl)-3-(4-(2-(2-(2-hydroxyethoxy)ethoxy) 
ethoxy)phenyl)-1H-pyrrol-2-yl)imino)-2H-pyrrole-3,5-diyl)bis(4,1-phenylene))bis(oxy))bis 
(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl))bis(oxy))bis(ethan-1-ol) (60). A solution of 56 
(5.3 g, 9.4 mmol), 59 (2.7 g, 5.0 mmol), in n-butanol (30 mL) was treated with NH4OAc (11.4g, 
148.0 mmol). The reaction mixture was refluxed for 5 hours, cooled to room temperature, diluted 
with brine (200 mL), and extracted with CH2Cl2 (3 × 200 mL). The combined organic fractions 
were dried (Na2SO4), filtered and concentrated under reduced pressure. The crude residue was 
purified by flash chromatography on a silica column (3:47 v/v MeOH:CH2Cl2) to afford the title 
compound as a dark blue solid (1.66 g, 1.6 mmol, 66.3 % yield). 1H NMR (500 MHz, CDCl3) δ 
7.91 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 8.6 Hz 1H), 7.79 (d, J = 8.6 Hz, 2H), 7.62 (s, 2H), 7.29 (s, 
1H), 7.01–6.92 (m, 3H), 6.89 (m, 3H), 6.80 (s, 1H), 6.20 (ddt, J = 16.5, 10.3, 6.0 Hz, 1H), 5.50 
(dd, J = 17.2, 1.5 Hz, 1H), 5.36 (dd, J = 10.3, 1.5 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 4.20 (m, 6H), 
3.98–3.65 (m, 30H). 13C NMR (125 MHz, CDCl3) δ 161.2, 159.3, 159.2, 158.7, 153.1, 151.4, 
146.9, 146.2, 144.5, 139.4, 133.2, 130.6, 130.3, 130.3, 129.8, 128.9, 127.2, 126.7, 126.1, 125.0, 
119.2, 115.3, 114.5, 74.9, 72.9, 71.2, 70.7, 70.0, 69.9, 67.7, 67.7, 62.0. m.p. = 158°C. HR-MS 
calculated for C53H62N3O13Cl2 [M+H]
+ m/z 1018.3660, found 1018.3654.  
(Z)-N-(5-(4-(allyloxy)-3,5-dichlorophenyl)-3-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-
siladodecan-12-yl)oxy)phenyl)-1H-pyrrol-2-yl)-3,5-bis(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-
115 
 
3-siladodecan-12-yl)oxy)phenyl)-2H-pyrrol-2-imine (61). To a solution of compound 60 (1.7 g, 
1.6 mmol) in anhydrous CH2Cl2 (30 mL) was added imidazole (1.1g, 16.3 mmol) and TBS-Cl (1.8 
g, 12.2 mmol). The reaction mixture was stirred overnight room temperature, poured in brine (150 
mL) and extracted with CH2Cl2 (3 × 60 mL). The combined organic fractions were dried (Na2SO4), 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography on a silica column (3:7 v/v EtOAc:hexanes) to afford the title compound as a dark 
blue film (929 mg, 0.7 mmol, 41.8 %). 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 8.7 Hz, 2H), 
7.95 (d, J = 8.7 Hz, 2H), 7.89 (d, J = 8.7 Hz, 2H), 7.71 (s, 2H), 7.05 (s, 1H), 7.02 (d, J = 8.7 Hz, 
2H), 6.96 (d, J = 3.7 Hz, 2H), 6.94 (d, J = 3.7 Hz, 2H), 6.87 (s, 1H), 6.20 (ddt, J = 16.3, 10.3, 5.9 
Hz, 1H), 5.49 (dd, J = 16.3, 1.5 Hz, 1H), 5.35 (dd, J = 10.4, 1.3 Hz, 1H), 4.63 (dt, J = 6.1, 1.3 Hz, 
2H), 4.22 (m, 6H), 3.98–3.58 (m, 30H), 0.92 (s, 27H), 0.09 (s, 18H). 13C NMR (125 MHz, CDCl3) 
δ 161.4, 159.7, 159.4, 158.9, 153.3, 151.5, 146.8, 146.1, 144.8, 139.5, 133.1, 130.6, 130.4, 130.2, 
129.9, 129.0, 127.1, 126.6, 126.1, 125.0, 119.3, 115.4, 115.3, 114.6, 111.2, 74.9, 73.0, 72.9, 71.2, 
71.2, 71.1, 70.1, 70.0, 69.9, 67.8, 67.7, 63.0, 26.2, 18.6, -5.0. m.p. = 153°C. HR-MS calculated for 
C71H104N3O13Si3Cl2 [M+H]
+ m/z 1360.6254, found 1360.6211. 
2,2',2''-(((((((7-(4-(Allyloxy)-3,5-dichlorophenyl)-5,5-difluoro-5H-4l4,5l4-dipyrrolo[1,2-
c:2',1'-f][1,3,5,2]triazaborinine-1,3,9-triyl)tris(benzene-4,1-diyl))tris(oxy))tris(ethane-2,1-
diyl))tris(oxy))tris(ethane-2,1-diyl))tris(oxy))tris(ethan-1-ol) (62). To a solution of 61 (929 mg, 
0.7 mmol) in anhydrous CH2Cl2 (30 mL) was treated with diisopropylethylamine (1.2 mL, 6.8 
mmol) and boron trifluoride etherate (1.7 mL, 13.7 mmol). The reaction mixture was stirred at 
room temperature for 2 hours, poured into H2O (100 mL) and extracted with CH2Cl2 (3 × 50 mL). 
The combined organic fractions were dried (Na2SO4), filtered, concentrated under reduced 
pressure and transferred to a flame-dried round-bottom flask. The intermediate was dissolved in 
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THF (40 mL) and treated with TBAF (1M in THF, 6.1 mL, 6.1 mmol) dropwise under a nitrogen 
atmosphere. After 10 min, the reaction was diluted with sat. NaHCO3 (100 mL) and extracted with 
CH2Cl2 (3 × 50 mL). The combined organic fractions were dried (Na2SO4), filtered and 
concentrated to afford the crude residue which was purified via flash chromatography on a silica 
column (7:93 v/v MeOH:CH2Cl2) to afford the title compound as a dark blue solid (464 mg, 0.4 
mmol, 63.6% yield over two-steps). 1H NMR (500 MHz, CDCl3) δ 8.06 (d, J = 8.5 Hz, 2H), 7.97 
(d, J = 9.3 Hz, 2H), 7.94 (d, J = 9.3 Hz, 2H), 7.93 (s, 2fH), 6.99–6.89 (m, 8H), 6.76 (s, 1H), 6.17 
(ddt, J = 16.4, 10.8, 5.8 Hz, 1H), 5.47 (d, J = 16.9 Hz, 1H), 5.32 (d, J = 10.3 Hz, 1H), 4.60 (d, J = 
6.0 Hz, 2H), 4.15 (dq, J = 5.6, 3.2 Hz, 6H), 3.92–3.55 (m, 30H), 3.09–2.99 (b, 2H), 2.85 (b, 1H). 
13C NMR (125 MHz, CDCl3) δ 162.0, 161.4, 160.6, 159.9, 152.4, 151.8, 146.9, 144.9, 144.1, 
141.2, 133.2, 132.4, 132.4, 132.3, 131.2, 130.8, 130.0, 129.9, 129.8, 129.8, 129.7, 125.9, 125.1, 
123.7, 119.1, 118.5, 116.5, 115.1, 114.9, 77.6, 77.6, 74.8, 72.8, 72.8, 71.1, 71.1, 70.6, 69.9, 69.8, 
69.8, 69.7, 67.7, 67.7, 67.7, 67.6, 61.9, 61.9. m.p. = 168°C. HR-MS calculated for 
C53H60BCl2F2N3O13 [M+Na]
+ m/z 1088.3384, found 1088.3448.  
Sodium 2-(2-(2-(4-(7-(4-(allyloxy)-3,5-dichlorophenyl)-5,5-difluoro-3,9-bis(4-(2-(2-(2-
(sulfonatooxy)ethoxy)ethoxy)ethoxy)phenyl)-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2] 
triazaborinin-1-yl)phenoxy)ethoxy)ethoxy)ethyl sulfate (63). A flame-dried round-bottom 
flask was charged with 62 (386 mg, 0.36 mmol), SO3-NMe3 (454 mg, 3.3 mmol) and anhydrous 
DMF (20 mL). The reaction was stirred at room temperature overnight. Volatiles were removed 
under reduced pressure, the crude residue was dissolved in H2O (10 ml), and loaded onto a 20 cc 
Sep-Pak cartridge preloaded with 5g C18 sorbent for reversed-phased purification (0-50% v/v 
MeCN:H2O gradient) to yield 19 as a blue solid (490 mg, 0.36 mmol, 99.0%). 
1H NMR (500 MHz, 
CD3OD) δ 8.05 (d, J = 8.6 Hz, 2H), 7.92 (s, 2H), 7.87 (d, J = 8.6 Hz, 2H), 7.83 (d, J = 8.6 Hz, 2H), 
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7.02–6.97 (s, 1H), 6.94 (d, J = 8.5 Hz, 2H), 6.77 (m, 4H), 6.15 (ddt, J = 16.3, 10.8, 5.6 Hz, 1H), 
5.46 (dd, J = 17.2, 1.6 Hz, 1H), 5.30 (dd, J = 10.6, 1.5 Hz, 1H), 4.54 (d, J = 5.8 Hz, 2H), 4.22–
4.12 (m, 8H), 4.04 (m, 4H), 3.89–3.83 (m, 6H), 3.78–3.71 (m, 18H). 13C NMR (125 MHz, DMSO-
d6) δ 162.8, 161.7, 161.3, 160.5, 160.5, 157.1, 156.1, 152.2, 151.4, 150.8, 146.9, 143.7, 140.8, 
133.7, 133.7, 133.1, 131.7, 131.2, 130.2, 130.1, 129.4, 126.8, 125.5, 124.6, 123.3, 119.7, 115.8, 
115.6, 115.3, 115.2, 115.2, 115.2, 75.1, 70.6, 70.4, 70.0, 69.6, 68.4, 60.9, 52.4, 44.8. HR-MS 
calculated for C53H57BCl2F2N3Na4O22S3 [M+Na]
+ m/z 1394.1625, found 1394.1606.  
Sodium 2-(2-(2-(4-(7-(3,5-dichloro-4-hydroxyphenyl)-5,5-difluoro-3,9-bis(4-(2-(2-(2-
(sulfonatooxy)ethoxy)ethoxy)ethoxy)phenyl)-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2] 
triazaborinin-1-yl)phenoxy)ethoxy)ethoxy)ethyl sulfate (64). A flame-dried round-bottom 
flask was charged with 63 (490 mg, 0.36 mmol, 1.0 equiv), 1,3-dimethylbarbituric acid (70.8 mg, 
0.45 mmol, 1.25 equiv), Pd(PPh3)4 (84.0 mg, 0.73 mmol, 0.2 equiv) and anhydrous DMF (40 mL). 
The reaction was stirred at room temperature overnight. All volatiles were removed under reduced 
pressure. The crude residue was treated with EtOAc and extracted with H2O (3 × 50 mL). The 
combined aqueous fractions were washed with Et2O (3 × 100 mL), concentrated to 5 mL, and 
loaded onto a 20 cc Sep-Pak cartridge preloaded with 5g C18 sorbent for reversed-phased 
purification (0-35% v/v MeCN:H2O gradient) to yield 19 as a dark pink solid (360 mg, 0.27 mmol, 
74.4%). 1H NMR (500 MHz, DMSO-d6) δ 8.44 (s, 2H), 8.25 (d, J = 8.3 Hz, 2H), 8.04–7.93 (m, 
3H), 7.87 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.5 Hz, 2H), 6.99 (d, J = 8.5 
Hz, 2H), 6.90 (s, 1H), 3.77 (dt, J = 24.1, 4.8 Hz, 18H), 3.58–3.51 (m, 18H). 13C NMR (125 MHz, 
DMSO-d6) δ 168.2, 164.3, 164.3, 160.4, 160.4, 159.1, 159.1, 158.6, 158.6, 158.0, 153.8, 153.8, 
148.4, 148.4, 144.6, 141.6, 140.3, 140.2, 133.0, 131.1, 130.6, 129.8, 127.4, 127.1, 126.9, 124.9, 
122.1, 115.3, 114.9, 113.9, 113.9, 110.0, 72.9, 70.6, 70.4, 70.0, 69.6, 68.1, 67.9, 65.7. m.p. = 
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237°C. HR-MS calculated for C50H53BCl2F2N3Na4O22S3 [M+H]
+ m/z 1354.1312, found 
1354.1329.  
3-(3,5-dichloro-4-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)oxy)phenyl)-5,5-
difluoro-1,7,9-triphenyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-f][1,3,5,2]triazaborinine (65). 26 
(77.86 mg, 0.13 mmol) was dissolved in anhydrous DMF (8mL) and treated with potassium iodide 
(111 mg, 0.68 mmol), cesium carbonate (218 mg, 0.68 mmol), and 4-bromomethylphenylboronic 
acid pinacol ester (35.7 mg, 0.12 mmol). The solution was heated at 115 °C over 3 days then cooled 
to room temperature and poured into brine. The aqueous layer was extracted with CH2Cl2 (5 × 10 
mL), dried with Na2SO4, concentrated under reduced pressure to afford the crude residue which 
was purified via flash chromatography on a silica column (1:3 v/v EtOAc:hexanes) to afford the 
title compound as a dark blue solid (7.74 mg, 0.0096 mmol, 7.2%). 1H NMR (500 MHz, CDCl3) 
δ 9.88 (s, 2H), 8.12 (d, J = 2.1 Hz, 1H), 8.09 – 8.05 (m, 2H), 7.95 (dd, J = 8.5, 2.1 Hz, 1H), 7.87 – 
7.83 (m, 5H), 7.69 – 7.67 (m, 3H), 7.52 (d, J = 15.7 Hz, 2H), 7.46 – 7.33 (m, 5H), 7.20 – 7.11 (m, 
2H), 7.01 (d, J = 8.6 Hz, 4H), 1.29 (s, 12H), 0.91 (s, 2H). 
2,6-dichloro-4-(5,5-difluoro-1,7,9-triphenyl-5H-5l4,6l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-3-yl)phenyl picolinate (66). A solution of 26 (31.9 mg, 0.06 mmol) in 
anhydrous CH2Cl2 (3 mL) was treated with 2-picolinic acid (27 mg, 0.22 mmol), DMAP (0.7 mg, 
0.01 mmol), and EDC (15.8 mg, 0.08 mmol). The resultant solution was stirred at room 
temperature for 1 hour. The reaction was diluted with H2O, the organic layer was separated and 
washed with a 1% aqueous HCl solution. The combined organic fractions were dried (Na2SO4), 
filtered, and concentrated to afford the crude residue which was purified via flash chromatography 
on a silica column (1:3 v/v EtOAc:hexanes) to afford the title compound as a teal film (19.9 mg, 
0.3 mmol, 53% yield). 1H NMR (500 MHz, CDCl3) δ 8.93 (d, J = 4.0 Hz, 1H), 8.37 (d, J = 7.6 Hz, 
119 
 
1H), 8.13–8.11, 8.09–8.05 (m, 6H), 7.98 (dt, J = 7.6, 1.8 Hz, 1H), 7.63 (ddd, J = 7.7, 4.7, 1.2 Hz, 
1H), 7.56–7.55 (m, 3H), 7.50–7.46 (m, 6H), 7.14 (s, 1H), 6.99 (s, 1H). 13C NMR (125 MHz, CDCl3) 
δ 162.7, 161.6, 153.7, 150.7, 146.4, 146.2, 145.6, 143.6, 137.6, 132.5, 132.1, 132.0, 131.9, 131.1, 
130.3, 130.1, 129.8, 129.6, 129.3, 129.1, 129.0, 128.9, 128.1, 126.6, 120.5, 118.5. HR-MS 
calculated for C38H23BCl2F2N4O2 [M-H]
+ m/z 687.1337, found 687.1345. 
Sodium 2-(2-(2-(4-(7-(3,5-dichloro-4-(picolinoyloxy)phenyl)-5,5-difluoro-3,9-bis(4-(2-(2-(2-
(sulfonatooxy)ethoxy)ethoxy)ethoxy)phenyl)-5H-4l4,5l4-dipyrrolo[1,2-c:2',1'-
f][1,3,5,2]triazaborinin-1-yl)phenoxy)ethoxy)ethoxy)ethyl sulfate (67). A round-bottom flask 
was charged with 64 (100 mg, 0.075 mmol) in H2O (3 mL). EDC (21.6 mg, 0.113 mmol), picolinic 
acid (27.7 mg, 0.225 mmol), and DMAP (1.38 mg, 0.011 mmol) were added. The reaction was 
stirred at room temperature for 2 hours and then washed with 1:2 v/v CH2Cl2:EtOAc (6 × 200 mL). 
The reaction was loaded onto a 1.0 mm thick preparative TLC plate for purification (9:11 v/v 
MeOH:CH2Cl2) to yield 67 (57.5 mg, 0.40 mmol, 53 %) as a blue solid.
 1H NMR (500 MHz, 
DMSO-d6) δ 8.89 (d, J = 4.7 Hz, 1H), 8.45 (s, 2H), 8.36 (d, J = 7.9 Hz, 1H), 8.25 (d, J = 8.5 Hz, 
2H), 8.15 (t, J = 8.1Hz, 1H), 8.06 – 7.97 (m, 3H), 7.88 (d, J = 8.4 Hz, 2H), 7.83 (dd, J = 7.8, 4.7 
Hz, 1H), 7.12 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 7.01 (d, J = 8.4 Hz, 2H), 6.89 (s, 1H), 
3.84–3.75 (m, 30H), 3.60 (s, 17H), 3.54 (s, 35H). HR-MS calculated for C56H56BCl2F2N4Na4O23S3 
[M+H]+ m/z 1459.1526, found 1459.1532. 
2-bromo-5-methoxyphenol (68). 3-methoxyphenol (3.0 g, 24.2 mmol) was taken up in CH2Cl2 
(300 mL) and N-bromosuccinimide (4.3 g, 24.2 mmol) was added in portions. The reaction was 
stirred at room temperature for 5 hours, then solvent removed under reduced pressure. Crude 
residue was purified using silica gel flash chromatography (1:9 v/v EtOAc:hexanes) to yield a 
colorless oil (4.78 g, 23.5 mmol, 97%). 1H NMR (500 MHz, CDCl3) δ 7.32 (dd, J = 8.8, 1.1 Hz, 
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1H), 6.60 (d, J = 2.8 Hz, 1H), 6.42 (dd, J = 8.8, 2.9 Hz, 1H), 3.77 (s, 3H). 13C NMR (125 MHz, 
CDCl3) δ 160.79, 153.22, 132.20, 108.67, 101.91, 101.13, 55.78. 
2-(allyloxy)-1-bromo-4-methoxybenzene (69). 68 (4.78 g, 23.5 mmol) was taken up in acetone 
(60 mL) and charged with K2CO3 (3.9 g, 28.2 mmol) then treated with allyl bromide (2.24 mL, 
25.9 mmol). The slurry was heated at 60°C for 2.5 hours then cooled down to room temperature, 
filtered thru celite, and rinsed with CH2Cl2 3 × 10 mL. The filtrate was concentrated and purified 
with silica gel chromatography (1:20 v/v EtOAc:hexanes) to yield the final product as colorless 
oil (4.76 g, 19.6 mmol, 83%). 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.7 Hz, 1H), 6.47 (d, J = 
2.7 Hz, 1H), 6.40 (dd, J = 8.7, 2.7 Hz, 1H), 6.06 (ddt, J = 17.2, 10.1, 5.0 Hz, 1H), 5.49 (dd, J = 
17.3, 1.5 Hz, 1H), 5.31 (dd, J = 10.6, 1.5 Hz, 1H), 4.58 (dt, J = 5.0, 1.6 Hz, 2H), 3.78 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 160.23, 155.76, 133.40, 132.72, 118.04, 106.44, 103.23, 101.55, 69.85, 
55.77. 
(E)-1-(2-(allyloxy)-4-methoxyphenyl)but-2-en-1-one (70). A flame dried 100 mL flask was 
charged with 69 (4.06 g, 16.7 mmol) and suspended into 60 mL dry THF and cooled to -78°C in 
an acetone dry ice bath and treated dropwise with 2.5 M n-butyl Li (7.35 mL, 18.4 mmol). After 
30 mins at -78°C the reaction was treated with crotonaldehyde (1.7 g, 20.0 mmol) and brought to 
room temperature upon addition completion. Reaction was allowed to stir at room temperature for 
3 hours then quenched with 25 mL of a saturated NH4Cl solution. The solution was diluted with 
brine and extracted with 3 × 15 mL EtOAc, organic layer was dried with Na2SO4 and concentrated 
in vacuo. The crude residue was suspended in DMSO (10 mL) and charged with 2-iodoxybenzoic 
acid (4.67 gg, 16.7 mmol). The slurry was stirred at room temperature for 1 hour then quenched 
with brine (100 mL) and filtered. The filtrate was extracted with 4 × 15 mL, the combined organic 
fractions were dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude reside 
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was purified using flash chromatography and 1:10 EtOAc to hexanes to isolate final product as a 
yellow oil (1.44 g, 6.2 mmol, 32%). 1H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 16.5 Hz, 1H), 7.47 
(d, J = 8.6 Hz, 1H), 6.66 (d, J = 16.4 Hz, 1H), 6.50 (dd, J = 8.6, 2.5 Hz, 1H), 6.43 (d, J = 2.4 Hz, 
1H), 6.06 (ddt, J = 17.5, 10.4, 5.1 Hz, 1H), 5.43 (dd, J = 17.2, 1.6 Hz, 1H), 5.32 (dd, J = 10.7, 1.5 
Hz, 1H), 4.58 (d, J = 5.2 Hz, 2H), 3.80 (s, 3H), 2.34 (s, 3H).13C NMR (125 MHz, CDCl3) δ 199.25, 
163.11, 158.92, 138.95, 132.92, 129.93, 125.73, 125.67, 118.10, 116.80, 106.06, 99.76, 69.42, 
55.68, 27.26.  
1-(2-(allyloxy)-4-methoxyphenyl)-3-methyl-4-nitrobutan-1-one (71). 70 (1.44 g, 6.1 mmol) 
was dissolved into ethanol (40 mL) and nitromethane (3.3 mL, 61 mmol) then charged with 20% 
w/v KOH solution (0.4 mL, 7.4 mmol). The solution was refluxed at 70°C for 3 hours then cooled 
to room temperature and reduced under vacuum. The crude residue was purified with silica gel 
flash chromatography with 1:3 EtOAc:hexanes to isolate the final product as a pale yellow oil 
(1.37 g, 5.8 mmol, 96%). 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.8 Hz, 1H), 6.40 (dd, J = 8.8, 
2.2 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 5.98 (ddt, J = 17.3, 10.7, 5.4 Hz, 1H), 5.33 (dd, J = 17.3, 1.5 
Hz, 1H), 5.24 (dd, J = 10.5, 1.4 Hz, 1H), 4.49 (d, J = 5.6 Hz, 2H), 4.40 (dd, J = 11.8, 5.4 Hz, 1H), 
4.21 (dd, J = 11.8, 7.6 Hz, 1H), 3.70 (s, 3H), 2.93 (dd, J = 14.2, 6.6 Hz, 2H), 2.87 – 2.79 (m, 1H), 
0.96 (d, J = 6.5 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 197.40, 164.77, 160.04, 132.77, 132.59, 
120.69, 118.73, 105.98, 99.32, 81.10, 69.64, 55.62, 47.34, 29.17, 17.72. 
 (Z)-5-(2-(allyloxy)-4-methoxyphenyl)-N-(5-(2-(allyloxy)-4-methoxyphenyl)-3-methyl-1H-
pyrrol-2-yl)-3-methyl-2H-pyrrol-2-imine (72). 71 (1.28 g, 4.3 mmol) was treated with 
ammonium acetate (6.73 g, 86 mmol) and dissolved in 15 mL of methanol and refluxed at 70°C 
for 10 hours. Reaction was cooled and concentrated under reduce pressure. The crude residue was 
washed with brine and extracted with 4 × 15 mL CH2Cl2, organic layers were dried with Na2SO4 
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and concentrated to be purified with silica gel flash chromatography with 1:50 MeOH: CH2Cl2 to 
isolate the final product as a green film (170 mg, 0.34 mmol, 16%).1H NMR (400 MHz, CD2Cl2) 
δ 7.89 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 1.1 Hz, 2H), 6.58 (dd, J = 8.7, 2.4 Hz, 2H), 6.53 (d, J = 2.4 
Hz, 2H), 6.06 (ddt, J = 17.3, 10.5, 5.2 Hz, 2H), 5.36 (d, J = 17.3 Hz, 2H), 5.23 (dd, J = 10.6, 1.4 
Hz, 2H), 4.68 (d, J = 5.2 Hz, 4H), 3.83 (s, 3H), 2.06 (s, 3H). 13C NMR (100 MHz, CD2Cl2) δ 
162.18, 158.32, 152.87, 139.41, 133.30, 130.37, 119.21, 117.87, 115.25, 106.39, 100.35, 69.96, 
55.67, 20.74, 11.17. 
3,7-bis(2-(allyloxy)-4-methoxyphenyl)-5,5-difluoro-1,9-dimethyl-5H-4l4,5l4-dipyrrolo[1,2-
c:2',1'-f][1,3,5,2]triazaborinine (73). 72 (170 mg, 0.34 mmol) was suspended into 10 mL of dry 
CH2Cl2 then charged with anhydrous diisopropylethylamine (0.42 mL, 3.4 mmol) and then 
dropwise addition of boron trifluoride etherate (0.82 mL, 0.34 mmol). The reaction stirred at room 
temperature for 1.5 hours extracted with brine and 3 × 10 mL CH2Cl2 then dried (Na2SO4) and 
concentrated under reduced pressure. The crude residue was purified with silica gel flash 
chromatography with 3:1  CH2Cl2 to hexanes to isolate the final product as a dark green film (40.4 
mg, 0.07 mmol, 21%). 1H NMR (500 MHz, CD2Cl2) δ 7.79 (d, J = 8.7 Hz, 2H), 6.66 (s, 2H), 6.55 
(dd, J = 8.7, 2.3 Hz, 2H), 6.49 (d, J = 2.4 Hz, 2H), 6.02 (ddt, J = 17.2, 10.4, 5.0 Hz, 2H), 5.40 – 
5.36 (m, 2H), 5.27 – 5.25 (m, 2H), 4.56 (d, J = 4.9 Hz, 4H), 3.82 (s, 6H), 2.34 (s, 6H). 19F NMR 
(470 MHz, CD2Cl2) δ -133.08 (dd, J = 63.0, 31.4 Hz). 
2,12-dimethoxy-6,8-dimethyl-14,15-dioxa-4b1,7,7a1l4-triaza-14al4-
borabenzo[6,7]indeno[3,4-ef]aceanthrylene (74). 73 (15.9 mg,0.03 mmol) was dissolved into 2 
mL of CH2Cl2 and charged with 1,3-dimethylbarbituric acid (22.8 mg, 0.15 mmol) and Pd(PPh3)4 
(1.68 mg, 0.0015 mmol). The solution was stirred at 40°C overnight then washed with saturated 
NH4Cl (3 × 6 mL) then extracted with brine and 2 × 5 mL CH2Cl2. Reaction was then concentrated 
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under reduced pressure and purified using flash chromatography and 1:9 EtOAc to hexanes to 
yield the final product as a green film (4.9 mg, 0.01 mmol, 39%). 1H NMR (500 MHz, CD2Cl2) δ 
7.66 (d, J = 8.7 Hz, 2H), 6.72 (d, J = 1.3 Hz, 2H), 6.68 (dd, J = 8.7, 2.5 Hz, 2H), 6.50 (d, J = 2.5 
Hz, 2H), 3.80 (s, 6H), 2.44 (s, 6H). HR-MS calculated for C24H20BN3O4 [M+H]
+ m/z 426.1625, 
found 426.1613. 
2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-ol (75). A solution of triethylene glycol 
(105 g, 699 mmol), imadazole (30.9 g, 454 mmol), and CH2Cl2 (300 mL) was cooled to 0°C in an 
ice-bath and treated with TBS-Cl (52.7 mg, 350 mmol) in portions. After addition, reaction was 
brought to room temperature and stirred for 12 hours. The organic was washed with 1 N HCl 
aqueous solution (100 mL) then H2O (100 mL) and brine (100 mL). The combined organic 
fractions were dried (Na2SO4), filtered and concentrated to afford the crude residue which was 
purified via flash chromatography on a silica column (1:2 v/v EtOAc:hexanes) to afford the title 
compound as a colorless oil (56.1 g, 212 mmol, 61%).  
2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl 4-methylbenzenesulfonate (76). A 
round-bottom flask was charged with 75 (56 g, 211 mmol), triethylamine (32 mL, 233 mmol), 
DMAP (0.52 g, 4 mmol), and CH2Cl2 (300 mL) then was cooled to 0°C in an ice-bath and treated 
with tosyl chloride (48.5 g, 254 mmol). After 12 hours, 1 N HCl aqueous solution (100 mL) was 
added, the organic layer was separated and washed sequentially with H2O (100 mL) and brine (100 
mL). The combined organic fractions were dried (Na2SO4), filtered, and concentrated to afford the 
crude residue which was purified via flash chromatography on a silica column (1:20 v/v 
EtOAc:hexanes) to afford the title compound as a yellow oil (51.6 g, 123 mmol, 93% yield). 1H 
NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 4.14 – 4.12 (m, 2H), 
3.72 (t, J = 5.4 Hz, 2H), 3.68 – 3.65 (m, 2H), 3.55 (s, 4H), 3.50 (t, J = 5.4 Hz, 2H), 2.42 (s, 3H), 
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0.86 (s, 9H), 0.03 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 170.63, 144.99, 133.16, 130.02, 128.19, 
72.90, 71.00, 70.87, 69.47, 68.89, 62.90, 26.12, 21.87, 18.58, -5.04. 
4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl)oxy)benzaldehyde (77). 4-
hydroxybenzaldehyde (8.14 g, 66.7 mmol), K2CO3 (10.9 g, 78.9 mmol), 76 (25.4 g, 60.7 mmol) 
were suspended in anhydrous DMF (50.0 mL) and heated at 80°C overnight. The reaction was 
cooled to room temperature and the volatiles were removed under reduced pressure. The resulting 
mixture was washed with brine (100 mL) and extracted with EtOAc (5 × 25 mL). The combined 
organic fractions were dried (Na2SO4), filtered, and concentrated under reduced pressure and was 
purified via flash chromatography on a silica column (3:17 v/v EtOAc:hexanes) to afford the title 
compound as a yellow oil (13.1 g, 35.6 mmol, 59% yield). 1H NMR (400 MHz, CDCl3) δ 9.77 (s, 
1H), 7.72 (d, J = 9.8 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H), 4.12 – 4.09 (m, 2H), 3.81 – 3.78 (m, 2H), 
3.67 (t, J = 5.3 Hz, 2H), 3.63 – 3.58 (m, 4H), 3.47 (t, J = 5.8 Hz, 2H), 0.80 (d, J = 1.1 Hz, 9H), -
0.03 (d, J = 1.2 Hz, 6H).13C NMR (100 MHz, CDCl3) δ 190.84, 164.00, 132.05, 130.14, 115.01, 
72.86, 71.09, 70.91, 69.59, 67.92, 62.88, 26.10, 18.52, -5.07. 
1-(2-(allyloxy)-4-methoxyphenyl)ethan-1-one (78). 2-hydroxy-4-methoxyacetophenone (7.03 g, 
42.3 mmol) was taken up in anhydrous DMF (25 mL) and charged with K2CO3 (81.7 g, 65 mmol) 
then treated with allyl bromide (5.1 mL, 59.2 mmol). The slurry was heated at 70°C for 18 hours 
then cooled down to room temperature and poured into brine. The aqueous solution was extracted 
with EtOAC (4 × 30 mL), the organic layers were combined and washed with brine (2 × 250 mL) 
then dried (Na2SO4) and concentrated under reduced pressure. The crude reside was purified with 
silica gel chromatography (3:17 v/v EtOAc:hexanes) to yield the final product as yellow oil (8.49 
g, 41.1 mmol, 97%). 1H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 8.7 Hz, 1H), 6.52 (dd, J = 8.7, 2.2 
Hz, 1H), 6.44 (s, 1H), 6.08 (ddt, J = 16.9, 10.6, 5.3 Hz, 1H), 5.44 (d, J = 17.3 Hz, 1H), 5.33 (d, J 
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= 10.5 Hz, 1H), 4.61 (d, J = 5.3 Hz, 2H), 3.83 (s, 3H), 2.60 (s, 3H). 13C NMR (125 MHz, CDCl3) 
δ 197.93, 164.60, 160.26, 132.89, 121.60, 118.53, 105.60, 99.57, 69.66, 55.74, 32.31. 
 (E)-1-(2-(allyloxy)-4-methoxyphenyl)-3-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-
siladodecan-12-yl)oxy)phenyl)prop-2-en-1-one (79). 78 (2.0 g, 9.8 mmol) and 77 (3.6 g, 9.8 
mmol) was suspended in 15 mL of methanol and 20% KOH solution (3.3 mL, 11.7 mmol). 
Solution was heated at 50 °C for 15 hours. Methanol was removed under reduced pressure and 
extracted with brine and EtOAc 3 × 20 mL. The organic phase was dried over Na2SO3 and 
concentrate under reduced pressure then purified with silica gel chromatography with 1:3 EtOAc 
to hexanes to yield a yellow oil (1.77 g, 4 mmol, 41%). 1H NMR (500 MHz, CDCl3) δ 7.79 (d, J 
= 8.6 Hz, 1H), 7.67 (d, J = 15.7 Hz, 1H), 7.54 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 15.7 Hz, 1H), 6.93 
(d, J = 8.7 Hz, 2H), 6.59 (dd, J = 8.6, 2.1 Hz, 1H), 6.50 (d, J = 2.2 Hz, 1H), 6.07 (ddd, J = 22.3, 
10.3, 5.1 Hz, 1H), 5.47 (d, J = 18.7 Hz, 1H), 5.29 (d, J = 11.4 Hz, 1H), 4.64 (d, J = 5.0 Hz, 2H), 
4.19 – 4.17 (m, 2H), 3.91-3.88 (m, 5H), 3.79 (t, J = 5.4 Hz, 2H), 3.75 – 3.70 (m, 4H), 3.59 (t, J = 
5.4 Hz, 2H), 0.91 (s, 9H), 0.08 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 190.74, 159.46, 141.93, 
133.12, 132.70, 130.18, 128.53, 125.44, 123.05, 118.15, 115.12, 110.00, 105.76, 100.02, 72.97, 
71.18, 71.03, 69.88, 69.63, 67.75, 62.97, 55.79, 26.18, -5.00. 
1-(2-(allyloxy)-4-methoxyphenyl)-4-nitro-3-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-
siladodecan-12-yl)oxy)phenyl)butan-1-one (80). 79 (0.6 g, 1.08 mmol) was suspended in 20 mL 
ethanol, nitromethane (1.15 mL, 21.5 mmol), and KOH (0.08 g, 1.3 mmol). Mixture was refluxed 
at 70°C for 4 hours then reduced under vacuum and purified with silica gel flash chromatography 
using 2:3 EtOAc to hexanes to yield an yellow oil (0.62 g, 1.0 mmol, 93%). 1H NMR (500 MHz, 
CDCl3) δ 7.74 (d, J = 8.8 Hz, 1H), 7.13 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 6.49 (dd, J = 
8.8, 2.2 Hz, 1H), 6.43 (s, 1H), 6.04 (ddt, J = 17.1, 10.9, 5.5 Hz, 1H), 5.41 (d, J = 17.3 Hz, 1H), 
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5.33 (d, J = 10.5 Hz, 1H), 4.73 (dd, J = 12.2, 6.2 Hz, 1H), 4.60 – 4.54 (m, 3H), 4.09 – 4.07 (m, 
3H), 3.84 – 3.76 (m, 7H), 3.71 – 3.66 (m, 4H), 3.56 (t, J = 5.4 Hz, 2H), 3.41 (d, J = 7.0 Hz, 2H), 
0.90 (d, J = 1.1 Hz, 9H), 0.07 (s, 6H). 13C NMR (125 MHz, CDCl3) δ 196.84, 164.91, 160.06, 
158.33, 133.05, 132.51, 132.10, 128.76, 120.78, 119.07, 115.09, 106.05, 99.55, 80.55, 72.94, 
71.08, 70.99, 69.92, 69.79, 67.62, 62.98, 55.74, 47.09, 39.32, 26.19, 18.59, -4.98, -5.01. 
 (Z)-5-(2-(allyloxy)-4-methoxyphenyl)-N-(5-(2-(allyloxy)-4-methoxyphenyl)-3-(4-((2,2,3,3-
tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl)oxy)phenyl)-1H-pyrrol-2-yl)-3-(4-((2,2,3,3-
tetramethyl-4,7,10-trioxa-3-siladodecan-12-yl)oxy)phenyl)-2H-pyrrol-2-imine (81). 80 (0.62 
g, 1.0 mmol) was treated with ammonium acetate (1.5 g, 20 mmol) and dissolved in 15 mL of 
methanol and refluxed at 70°C for 14 hours. Reaction was cooled and concentrated under reduce 
pressure. The crude residue was washed with DI H2O (3 × 75) and brine (75 mL) organic phases 
were combined, dried with Na2SO4 and concentrated to be purified with silica gel flash 
chromatography with 1:3 EtOAc:hexanes to isolate the final product as a blue film (95 mg, 0.08 
mmol, 8.3%).1H NMR (400 MHz, CD2Cl2) δ 8.01 (t, J = 8.7 Hz, 7H), 7.24 (s, 1H), 6.99 (d, J = 8.8 
Hz, 4H), 6.65 (d, J = 10.8 Hz, 2H), 6.60 (s, 2H), 6.11 (ddt, J = 15.8, 10.5, 5.2 Hz, 2H), 5.43 – 5.26 
(m, 5H), 4.73 (d, J = 5.1 Hz, 4H), 4.21 – 4.19 (m, 4H), 3.89 – 3.87 (m, 9H), 3.79 – 3.77 (m, 4H), 
3.73 – 3.69 (m, 8H), 3.58 – 3.56 (m, 5H), 0.92 (s, 18H), 0.09 (s, 12H). 
(Z)-2-(2-((5-(2-hydroxy-4-methoxyphenyl)-3-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-
siladodecan-12-yl)oxy)phenyl)-1H-pyrrol-2-yl)imino)-3-(4-((2,2,3,3-tetramethyl-4,7,10-
trioxa-3-siladodecan-12-yl)oxy)phenyl)-2H-pyrrol-5-yl)-5-methoxyphenol (82). 81 (94.8 mg, 
0.08 mmol) was dissolved into 10 mL of CH2Cl2 and charged with 1,3-dimethylbarbituric acid (40 
mg, 0.25 mmol) and Pd(PPh3)4 (5 mg. 0.004 mmol). The solution was stirred at room temperature 
for 7 hours. Reaction was then concentrated under reduced pressure and purified using flash 
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chromatography and 1:1 EtOAc to hexanes to yield the final product as a dark green film (15.2 
mg, 0.014 mmol, 18%). 1H NMR (500 MHz, CD2Cl2) δ 8.04 (d, J = 8.6 Hz, 4H), 7.43 (d, J = 8.8 
Hz, 2H), 7.12 (s, 2H), 7.01 (d, J = 8.7 Hz, 4H), 6.26 – 6.22 (m, 4H), 4.22 – 4.20 (m, 4H), 3.91 – 
3.89 (m, 4H), 3.80 (t, J = 5.2 Hz, 1H), 3.75 – 3.69 (m, 8H), 3.58 (t, J = 5.2 Hz, 4H), 3.38 (s, 6H), 
3.27 (s, 1H), 0.93 (s, 18H), 0.11 (s, 12H).13C NMR (125 MHz, CD2Cl2) δ 164.60, 163.53, 159.48, 
151.71, 141.08, 140.09, 130.72, 128.75, 126.52, 114.61, 112.23, 109.99, 108.98, 108.27, 101.19, 
72.96, 71.06, 70.91, 69.88, 67.81, 62.98, 55.02, 29.92, 28.41, 25.94, 18.48, -5.32. 
(Z)-5-(4-methoxy-2-((4-(3,3,4,4-tetramethyl-1l3,2,5-bromadioxolan-1-
yl)benzyl)oxy)phenyl)-N-(5-(4-methoxy-2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzyl)oxy)phenyl)-3-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-
yl)oxy)phenyl)-1H-pyrrol-2-yl)-3-(4-((2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecan-12-
yl)oxy)phenyl)-2H-pyrrol-2-imine (83).  82 (15.2 mg, 0.014 mmol) was dissolved in anhydrous 
DMF (10 mL) and charged with potassium iodide (19 mg, 0.11 mmol), cesium carbonate (23 mg, 
0.07 mmol), and 4-bromomethylphenylboronic acid pinacol ester (21 mg, 0.07 mmol). Reaction 
was stirred at room temperature for 10 hours then poured into brine and extracted with EtOAc (4 
× 10 mL). Organic phases were combined and dried over Na2SO4, filtered, concentrated under 
vacuum, and was purified via flash chromatography on a silica column (1:3 EtOAc to hexanes) to 
yield the final compound as a green film (11.4 mg, 0.008 mmol, 57%). 1H NMR (500 MHz, CD2Cl2) 
δ 7.98 – 7.94 (m, 6H), 7.79 (d, J = 7.9 Hz, 4H), 7.49 (d, J = 7.8 Hz, 4H), 7.24 (s, 2H), 6.97 (d, J = 
8.8 Hz, 4H), 6.48 (s, 2H), 6.25 (d, J = 8.8 Hz, 2H), 4.20– 4.17 (m, 4H), 3.89 – 3.87 (m, 4H), 3.79 
– 3.77 (m, 4H), 3.73 – 3.67 (m, 14H), 3.57 – 3.55 (m, 5H), 1.34 (s, 20H), 1.28 (s, 6H), 0.91 (s, 
18H), 0.09 (s, 12H). 
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 (Z)-2-(2-((5-(2-hydroxy-4-methoxyphenyl)-3-(4-(2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)phenyl)-1H-pyrrol-2-yl)imino)-3-(4-(2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)phenyl)-2H-pyrrol-5-yl)-5-methoxyphenol (84). 82 (28.3 mg, 
0.03 mmol) was dissolved into CH2Cl2 (10 mL) and treated with 2-picolinic acid (16 mg, 0.13 
mmol), EDC (13.4 mg, 0.07 mmol), and DMAP (0.3 mg, 0.003 mmol). Reaction was stirred for 
24 hours at room temperature then washed with DI H2O (3 × 30 mL) and brine (1 × 50 mL). 
Organic layer was dried (Na2SO4), filtered, concentrated under vacuum, and purified using silica 
gel flash chromatography (1:50 MeOH to CH2Cl2) to yield a blue film (12.1 mg, 0.009 mmol, 
35%). 1H NMR (400 MHz, CD2Cl2) δ 8.49 (d, J = 4.6 Hz, 1H), 8.12 (d, J = 7.8 Hz, 1H), 8.00 (d, J 
= 8.8 Hz, 2H), 7.80 (dd, J = 8.7, 5.6 Hz, 3H), 7.66 – 7.60 (m, 3H), 7.41 – 7.32 (m, 2H), 7.32 (s, 
1H), 7.15 (s, 2H), 7.03 (d, J = 8.7 Hz, 2H), 6.96 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 6.55 
(d, J = 9.3 Hz, 2H), 4.16 (dt, J = 9.7, 4.7 Hz, 4H), 3.91 (s, 3H), 3.85 (dd, J = 9.5, 4.7 Hz, 7H), 3.75 
(t, J = 4.7 Hz, 4H), 3.70 – 3.63 (m, 8H), 3.53 (t, J = 5.1 Hz, 4H), 0.88 (d, J = 1.1 Hz, 18H), 0.06 
(d, J = 1.2 Hz, 12H). 
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APPENDIX C 
REACTION SCHEMES AND NMR SPECTRA 
 
 
Figure C.1. Reaction scheme of synthesis of 15. 
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Figure C.2. 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) of 14. 
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Figure C.3. 1H NMR (400 MHz, CDCl3) spectra of 15. 
 
Figure C.4. Reaction Scheme synthesis of 20. 
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Figure C.5. 1H NMR (500 MHz, CD3OD) and 
19F NMR (470 MHz, CD3OD) spectra of 16. 
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Figure C.6. 1H NMR (500 MHz, CD3OD) and 
19F NMR (470 MHz, CD3OD) spectra of 17. 
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Figure C.7. 1H NMR (500 MHz, CDCl3) and 
19F NMR (375 MHz, CDCl3) spectra of 18. 
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Figure C.8. Reaction Scheme synthesis of 26. 
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Figure C.9. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 21. 
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Figure C.10. 1H NMR (500 MHz, DMSO-d6) and 
13C NMR (125 MHz, DMSO-d6) spectra of 
22. 
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Figure C.11. 1H NMR (500 MHz, acetone-d6) and 
13C NMR (125 MHz, acetone-d6) spectra of 23. 
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Figure C.12. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 24. 
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Figure C.13. 1H NMR (500 MHz, DMSO-d6) and 
13C NMR (125 MHz, DMSO-d6) spectra of 25. 
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Figure C.14. 1H NMR (500 MHz, DMSO-d6) and 
13C NMR (125 MHz, acetone-d6) spectra of 26. 
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Figure C.15. Reaction Scheme synthesis of 32. 
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Figure C.16. 1H NMR (500 MHz, acetone-d6) and 
13C NMR (125 MHz, acetone-d6) spectra of 
28. 
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Figure C.17. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 30. 
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Figure C.18. 1H NMR (500 MHz, DMSO-d6) spectra of compound 31. 
 
 
Figure C.19. Reaction Scheme of compound 37 synthesis. 
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Figure C.20. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 33. 
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Figure C.21. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 34. 
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Figure C.22. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 35. 
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Figure C.23. Reaction scheme for the synthesis of compound 42. 
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Figure C.24. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 38. 
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Figure C.25. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 39. 
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Figure C.26. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 40. 
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Figure C.27. Reaction scheme for compound 45. 
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Figure C.28. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 43. 
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Figure C.29. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 44. 
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Figure C.30. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 45. 
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Figure C.31. Reaction scheme for synthesis of 49. 
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Figure C.32. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 46. 
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Figure C.33. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 47. 
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Figure C.34. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 48. 
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Figure C.35. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 49. 
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Figure C.36. Reaction scheme of compound 51 synthesis. 
 
 
 
 
 
 
 
 
Figure C.37.  Reaction scheme for compound 56. 
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Figure C.38. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 52. 
164 
 
 
 
 
Figure C.39. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 53. 
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Figure C.40. 1H NMR (400 MHz, CDCl3) and 
13C NMR (100 MHz, CDCl3) spectra of 54. 
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Figure C.41. 1H NMR (400 MHz, CD3OD) and 
13C NMR (100 MHz, CD3OD) spectra of 55. 
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Figure C.42. 1H NMR (400 MHz, CD3OD) and 
13C NMR (100 MHz, CD3OD) spectra of 56. 
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Figure C.43. Reaction scheme for synthesis of compound 64. 
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Figure C.44. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 57. 
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Figure C.45. 1H NMR (400 MHz, CD3OD) and 
13C NMR (100 MHz, CD3OD) spectra of 58. 
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Figure C.46. 1H NMR (400 MHz, CD3OD) and 
13C NMR (100 MHz, CD3OD) spectra of 59. 
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Figure C.47. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 60. 
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Figure C.48. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 61. 
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Figure C.49. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 62. 
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Figure C.50. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 63. 
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Figure C.51. 1H NMR (500 MHz, DMSO-d6) and 
13C NMR (125 MHz, DMSO-d6) spectra of 64. 
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Figure C.52. Reaction scheme of compound 65. 
 
 
Figure C.53. 1H NMR (500 MHz, CDCl3) spectra of compound 65. 
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Figure C.54. Reaction scheme of compound 66. 
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Figure C.55. 1H NMR (500 MHz, CDCl3) and 
13C NMR (125 MHz, CDCl3) spectra of 66. 
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Figure C.56. Reaction scheme of compound 67. 
 
 
 
 
Figure C.57. 1H NMR (500 MHz, DMSO-d6) spectrum of 67. 
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Figure C.58. Reaction scheme of compound 74. 
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Figure C.59. 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) spectrum of 68. 
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Figure C.60. 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectrum of 69. 
184 
 
 
Figure C.61. 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) spectrum of 70. 
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Figure C.62. 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectrum of 71. 
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Figure C.63. 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectrum of 72. 
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Figure C.64. 1H NMR (500 MHz, CDCl3) and 19F NMR (470 MHz, CDCl3) spectrum of 73. 
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Figure C.65. 1H NMR (500 MHz, CDCl3) spectrum of 74. 
 
 
 
 
Figure C.66. Reaction scheme of compound 77. 
189 
 
 
Figure C.67. 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectrum of 76. 
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Figure C.68. 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) spectrum of 77. 
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Figure C.69. Reaction scheme of compound 82. 
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Figure C.70. 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) spectrum of 78. 
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Figure C.71. 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) spectrum of 79. 
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Figure C.72. 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) spectrum of 80. 
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Figure C.73. 1H NMR (400 MHz, CDCl3) spectrum of 81. 
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Figure C.74. 1H NMR (500 MHz, CDCl3) and 13C NMR (125 MHz, CDCl3) spectrum of 82. 
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Figure C.75. Reaction scheme for compound 83. 
 
 
Figure C.76. 1H NMR (500 MHz, CDCl3) spectrum of 83. 
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Figure C.77. Reaction scheme for compound 84. 
 
Figure C.78. 1H NMR (500 MHz, CDCl3) spectrum of 84. 
 
 
 
 
